UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-K

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended: July 31, ~~2022~~2023

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 000-56356

POINT OF CARE NANO-TECHNOLOGY INC.
(Exact name of registrant as specified in its charter)

Nevada		27-2830681
(State or other jurisdiction of incorporation or		(I.R.S. Employer Identification No.)
organization)

109 Ambersweet Way

Davenport, FL 33897

(Address of principal executive offices)

(732)723-7395

Issuer’s telephone number

With a copy to:

Louis A. Bevilacqua, Esq.

Bevilacqua, PLLC

1050 Connecticut Ave, NW, Suite 500

Washington, DC 20036

T: (202) 869-0888

F: (202) 203-8665

lou@bevilacquapllc.com

Securities registered under Section 12(b) of the Act:

Title of each class		Name of each exchange on which registered
None		N/A

Securities registered under Section 12(g) of the Act:
Common Stock, $0.001 par value
(Title of class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes o No x

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes o No x

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes x No o

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o Accelerated filer o Non-accelerated ~~Filer~~filer x Smaller reporting company x ~~(Do not check if a smaller reporting company)~~ Emerging Growth Company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act o

Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

Yes o No x

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter.

At ~~January~~July 31, ~~2022~~2023 aggregate market value of the voting and non-voting common equity held by non-affiliates was approximately $241,~~820~~960,~~000, based~~ based on a valuation of $30.0010 per share of Common Stock (the closing sales price of ~~the~~our ~~Company’s~~ Common Stock on January 31, 2022).

As of October 2529, ~~2022~~2024, there were ~~940~~72,690,621 shares of Common Stock issued and outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

None

TABLE OF CONTENTS

		Page
	PART I
Item 1	Business	4
Item 1A	Risk Factors	67
Item 1B	Unresolved Staff Comments	1113
Item 2	Properties	11
Item 1C	Cybersecurity	13
Item 3	Legal Proceedings	11
Item 2	Properties	14
Item 3	Legal Proceedings	14
Item 4	Mine Safety Disclosure	14
	PART II
Item 5	Market for ~~Registrant’s~~ Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	1214
Item 6	Selected Financial Data	1315
Item 7	Management’s Discussion and Analysis of Financial Condition and Results of Operations	1315
Item 7A	Quantitative and Qualitative Disclosure about Market Risk	1821
Item 8	Financial Statements and Supplementary Data	1821
Item 9	Change In and Disagreements with Accountants on Accounting and Financial Disclosure	1821
Item 9A	Controls and Procedures	1821
Item 9B	Other Information	1923
	PART III
Item 10	Directors, Executive Officers and Corporate Governance	2024
Item 11	Executive Compensation	2225
Item 12	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	2327
Item 13	Certain Relationships and Related Transactions, and Director Independence	2327
Item 14	Principal Accounting Fees and Services	2428
	PART IV
Item 15	Exhibits, Financial Statement Schedules	2529
Signatures		2631

Forward Looking Statements

This Annual Report on Form 10-K contains forward-looking statements which relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” should,”” expect,” “plan,” “anticipate,” “believe”, “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks in the section entitled “Risk Factors” included herein that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Important factors that may cause actual results to differ from projections include, for example:

● the success or failure of management’s efforts to implement our plan of operation; ● the ~~Company~~success or failure of management’s ~~plan~~efforts ofto ~~operation~~build its “EZ Saliva” business;

●

the ability of the Company to fund its operating expenses;

●

the ability of the Company to compete with other companies that have a similar plan of operation;

●

the effect of changing economic conditions impacting our plan of operation;

●

the ability of the Company to meet the other risks as may be described in future filings with the SEC.

While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested herein. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results. The safe harbor for forward-looking statements provided in the Private Securities Litigation Reform Act of 1995 does not apply to this annual report.

Unless otherwise noted, all references in this Form 10-K to “Point of Care Nano-Technology,” “PCNT,” the “Company,” “we,” “us,” “our” and similar terms and expressions shall mean Point of Care Nano-Technology, Inc., a Nevada corporation ~~formerly known as Unique Growing Solutions~~, ~~Inc.,~~ and its subsidiaries.

PART I

Item 1. Business

Overview

~~Our~~On ~~plan~~April of11, ~~operation~~2022, ~~for~~we, ~~the~~through ~~next~~our 12wholly ~~months~~owned issubsidiary, toDuo ~~seek~~Sciences ~~and~~Inc. ~~acquire~~(“DSI”), ~~new~~acquired ~~business~~an ~~assets~~exclusive inlicense ~~the~~to ~~life~~distribute certain ~~sciences~~intellectual ~~industry~~property ~~and~~in ~~begin~~animal ~~operations with~~nutrition ~~these~~and ~~new~~animal ~~assets.~~supplements Wefrom doCedoga ~~not~~Consulting, ~~intend~~LLC, toand ~~limit~~on ~~our activities~~April to19, a2022, ~~particular~~we, ~~field~~through DSI, ~~within~~signed ~~the~~an ~~life~~exclusive ~~sciences~~sales ~~sector~~ and wepromotion ~~have~~agreement ~~not~~with ~~established~~Lucy ~~any~~Pet ~~particular~~Products ~~criteria~~Inc. ~~upon~~(“Lucy”) pursuant to which weLucy ~~shall~~will manufacture, ~~consider~~market aand ~~business~~distribute ~~opportunity~~on our behalf pet products created from the Cedoga intellectual property. ~~There~~Except ~~can~~for bean noinitial ~~assurances~~agreement ~~that~~fee of $100,000 we ~~will~~have benot ~~successful~~yet ~~with~~generated ~~our~~any ~~new~~other ~~business~~income ~~objective~~from this product line.

~~Our~~As ~~management~~further ~~will~~discussed ~~have~~below, ~~substantial~~on ~~flexibility~~May in20, ~~identifying~~2024, ~~and~~we ~~selecting~~acquired athe ~~prospective~~“EZ ~~new~~Saliva” testing business. ~~opportunity~~Our inplan ~~the~~of ~~life~~operation ~~sciences~~for the next ~~sector.~~12 Wemonths ~~are~~is ~~dependent~~to onbuild ~~the~~our ~~judgment~~EZ ofSaliva ~~our~~business ~~management~~(described inbelow) ~~connection~~through ~~with~~traditional ~~this~~direct ~~process.~~sales Inand ~~evaluating~~marketing aefforts ~~prospective~~to ~~business~~police ~~opportunity,~~departments and lab test companies in North America. There can be no assurances that we will ~~consider,~~be ~~among~~successful with our EZ Saliva business or any other business ~~factors,~~initiative ~~the~~we ~~following:~~may undertake.

● costs associated with pursuing a new business opportunity;

● growth potential of the new business opportunity;

● experiences, skills and availability of additional personnel necessary to pursue a potential new business opportunity;

● necessary capital requirements;

● the competitive position of the new business opportunity;

● stage of business development;

● the market acceptance of the potential products and services;

● proprietary features and degree of intellectual property; and

● the regulatory environment that may be applicable to any prospective business opportunity.

The foregoing criteria are not intended to be exhaustive and there may be other criteria that management may deem relevant. In connection with an evaluation of a prospective or potential business opportunity, management may be expected to conduct a due diligence review.

The time and costs required to pursue new business opportunities, which includes negotiating and documenting relevant agreements and preparing requisite documents for filing pursuant to applicable securities laws, cannot be ascertained with any degree of certainty.

Our management intends to devote such time as it deems necessary to carry out the Company’s affairs. The exact length of time required for the pursuit of any new potential business opportunities is uncertain. No assurance can be made that we will be successful in our efforts. We cannot project the amount of time that our management will actually devote to the Company’s business objectives.

We intend to conduct our activities so as to avoid being classified as an “Investment Company” under the Investment Company Act of 1940, and therefore, to avoid application of the costly and restrictive registration and other provisions of the Investment Company Act of 1940 and the regulations promulgated thereunder.

Recent Activities

On ~~April~~May 1130, ~~2022~~2024, we, ~~through~~engaged ~~our~~and ~~newly~~executed ~~established,~~an ~~wholly~~agreement ~~owned~~with ~~subsidiary,~~Fruci ~~Duo~~& ~~Sciences,~~Associates ~~Inc.~~II (“~~DSI~~Fruci”), ~~acquired~~PLLC anas ~~exclusive license~~our ~~from~~new ~~Cedoga~~independent ~~Consulting, LLC (“Cedoga”) to distribute in the USA, Canada and Mexico, certain intellectual property~~accountant offor ~~Cedoga relating to animal nutrition and animal supplements (~~the ~~“Cedoga~~fiscal ~~IP”).~~years Inended ~~exchange~~July ~~for these license rights~~31, ~~we agreed~~2023 toand ~~issue Cedoga 300,000 (post-reverse split (discussed below)) shares of our common stock~~2022. ~~Under the terms of the agreement, we will pay Cedoga royalties from sub-licensing the Cedoga IP on the following terms:~~

●On May ~~90%~~20, 2024, we entered into an asset purchase agreement (the “Agreement”) with Point of ~~net~~Care ~~royalties~~Nano-Technology, LLC (“Point”). Point was the company (unrelated to us) that Dr. Raouf Guirguis established to operate the business that Dr. Guirguis took back as a result of the consummation of the Spin Off Agreements (discussed below). Pursuant to this Agreement we agreed to acquire (the “Acquisition”) substantially all of the North American assets of Point (the “Assets”), consisting primarily of proprietary information and know-how for ~~sales~~the developing and ~~initial~~commercialization ~~payments~~of upkits for drug testing and to ~~$100~~diagnose illnesses through the testing of human saliva,~~000~~ referred to as the “EZ Saliva” test kits,~~000~~ ~~per~~and ~~calendar~~cash ~~year;~~in the amount of $101,400.

●In exchange ~~95%~~for ofthe ~~net~~Assets, ~~royalties~~we ~~received~~issued ~~for~~to ~~continuing~~Point ~~sales~~and/or ~~above~~its ~~$100~~designees 66,000,000 ~~per~~restricted ~~calendar~~shares ~~year;~~of ~~and~~our common stock (the “Consideration Shares”).

●Upon the 90closing of the Acquisition, which effected a change of control of the Company, Dr. Raouf Guirguis, the controlling member of Point, became a director of the Company and Chief Scientific Officer. Dr. Guirguis also acquired, directly and indirectly, 34,596,800 of the Consideration Shares, or approximately 48.4% of ~~any~~the ~~lump~~shares ~~sum~~of ~~up-front~~our ~~payment~~common ~~sub-licensing~~stock ~~fees~~outstanding after completion of the Acquisition. Mr. Nathan Keele, an associate of Dr. Guirguis and responsible for marketing efforts at Point, also was appointed to the board of directors of the Company. Mr. Keele will continue his marketing efforts at the Company. Mr. Keele acquired 18,903,200 of the Consideration Shares, or approximately 26.5% of the shares of our common stock outstanding after completion of the Acquisition.

WeNicholas ~~also~~DeVito, ~~gave~~our ~~Cedoga~~controlling anstockholder ~~option~~prior to ~~purchase~~the ~~200~~Acquisition through the 1,000 ~~(post~~shares of our super-~~reverse~~majority class A preferred stock (the ~~split~~“Preferred Stock”) that he held and through which he exercised eighty percent (80%) voting control over the Company, surrendered to us for cancellation the Preferred Stock and received, in exchange, 5,000,000 shares of our common stock. ~~when~~Mr. ~~net~~DeVito ~~sales~~will ofretain ~~the~~his positions ~~Cedoga~~as IPour ~~exceed~~Chief ~~$100~~Executive Officer,~~000~~ Chief Financial Officer,~~000~~ Treasurer and Secretary as well as his status as a member of our board of directors.

OnThe ~~April~~shares ~~19,~~of ~~2022,~~Company ~~we,~~common ~~through~~stock ~~DSI,~~issued ~~signed~~in anconnection ~~exclusive representative and sublicensing agreement~~ with ~~Lucy~~the ~~Pet~~Acquisition ~~Products~~(as ~~Inc.~~described ~~(“Lucy”~~above) ~~pursuant~~ towere ~~which~~issued ~~Lucy~~in ~~has~~accordance ~~agreed~~with toa ~~manufacture,~~private placement ~~market~~exemption ~~and distribute on our behalf pet products created~~ from ~~the~~registration ~~Cedoga~~under ~~IP.~~Section ~~Lucy paid us~~ 4(a)(2) ~~one-time sublicensing fee~~ of ~~$100,000 on~~ the ~~signing~~Securities ofAct ~~this agreement and will pay us royalties equal to 5%~~ of ~~their Net Revenue~~1933, ~~calculated and payable quarterly. Net Revenue, for purposes of our agreement with Lucy, is defined~~ as ~~total revenue less direct cost of materials~~amended, ~~manufacturing, packaging~~ and ~~delivery~~are ~~expenses~~considered ~~and less excise, sales or similar taxes~~“restricted securities.”

In connection with the Acquisition, we entered into a license agreement (the “License Agreement”) with Zeus Diagnostics, LLC (“Zeus”), a Delaware limited liability company controlled by Dr. Guirguis, pursuant to which we acquired an exclusive, in perpetuity, license, with a right to sublicense, in the Territory (Canada, the United States and Mexico) the “Zeus Know-How” which consists of all information related to the manufacture and commercialization of saliva tests derived from patents owned by Zeus. We paid Zeus a one-time, non-refundable up-front cash fee of $35,000 (which is creditable against other payments due) and will pay Zeus a royalty on “Net Sales” (as defined in the License Agreement) of seven and one-half Percent (7.5%) during each calendar quarter.

Following the closing of the Acquisition, our business has begun to focus on the EZ Saliva product commercialization activity previously carried on by Point.

The description of the agreement discussed above does not purport to be complete and the reader should refer to the full text of the agreements as exhibits to our Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on June 10, 2024.

On November 21, 2023, the Company changed transfer agents to ClearTrust, LLC from Sedona Equity Registrar & Transfer.

On February 28, 2023, the Company changed transfer agents to Sedona Equity Registrar & Transfer, Inc. from Vstock Transfer.

U.S. patent application 16/930,604 was allowed on March 29, 2023, and is expected to issue in the near future, further strengthening our subsidiary, DSI, intellectual property position and coverage for its DUOS products. The allowed claims are directed to an edible pet chew that contains a thermo-processed shell having a cylindrical shape and that includes cellulosic fibers, a humectant, and a gelling agent, and within the shell is a cold-formed filler that contains a fat mimicking composition and a thermally labile active containing an enzyme. The pet chew provides oral care properties and contains thermal labile nutrients and/or actives whose nutrient values and activities are preserved. The pet chews provide salivatory stimulation when consumed by the pet, which in combination with the other ingredients of the pet chew provide dental care properties to remove dental plaque, stain, and tartar on a tooth surface, as well as protection of the oral and perioral tissues. A continuation patent application seeking to further protect the pet chew oral care technology was also filed. The application has been assigned serial number 18/133,381 and the filing date was April 11, 2023.

On December 12, 2022, the Company entered into an asset purchase agreement with Global Foods Group, LLC (“GFG”) and its principal shareholder pursuant to which it agreed to acquire substantially all of the assets of GFG, consisting of assets relating to the sugar substitute that GFG has been developing, Jaca^®. In exchange for the Jaca related assets, the Company would issue to GFG and its designees 7,000,000 shares of our common stock. Upon the closing of this transaction, which would effect a change of control of the Company, Peter Ferrari, the principal of the controlling member of GFG, was to become the CEO and a director of the Company and Nicholas DeVito, the current CEO and controlling stockholder of the Company though the 1,000 shares of super-majority Class A Preferred Stock that he holds, was to retain his positions with the Company as Treasurer, Secretary and Chief Financial Officer and director, and he was to exchange his Class A Preferred shares for 2,000,000 shares of the common stock of the Company. On January 26, 2023, GFG terminated the asset purchase agreement in accordance with Section 3(e) of the agreement.

Historical Development

The Company was incorporated as “Alternative Energy & Environmental Solutions, Inc.” in the State of Nevada on June 10, 2010, to develop and license an innovative biotechnology for the environmentally friendly and cost-effective extraction of natural gas (coalbed methane) from low-producing, depleted and abandoned coal mines in the U.S. The Company was not successful in developing this business and discontinued its related operations.

The Company changed its name in 2014 to Unique Growing Solutions, Inc. and again in 2015 to Point of Care Nano-Technology, Inc.

On February 25, 2015, the Company entered into an exclusive worldwide license Agreement (the “License Agreement”) with Lamina Equities Corporation (“Lamina”), a private corporation owned by Dr. Raouf Guirguis. The License Agreement related to intellectual property for diagnosing illness in humans via a saliva test. In connection with signing the License Agreement, the Company appointed Dr. Guirguis as its Chief Executive Officer and issued to him 750,000 (post-reverse split) shares of its common stock, $0.0001 par value per share, resulting in a change of control of the Company with Dr. Guirguis becoming the Company’s majority stockholder. The Company did not have, however, the financial resources to pursue business development relating to the Lamina license.

On April 15, 2021, Dr. Guirguis resigned from all of his positions with the Company appointing Mr. Nicholas DeVito as Chief Executive Officer, Chief Financial Officer, President, Treasurer, Secretary and sole director. In consideration for the services that Mr. DeVito would be providing to the Company, the Company issued to Mr. DeVito 1,000 shares of its super-voting, non-convertible Class A preferred stock. These shares of non-convertible Class A preferred stock vote together with the outstanding shares of the Company’s common stock as a single class and represent eighty percent (80%) of all votes entitled to be voted at any annual or special meeting of the Company’s shareholders or action by written consent of shareholders. This issuance of the 1,000 shares of Series A non-convertible preferred stock to Mr. Devito constituted a change of control of the Company giving Mr. Devito control of 80% of the voting power of the Company.

The Company and Dr. Guirguis entered into a certain assignment and assumption agreement and a separate transfer agreement pursuant to which the Company transferred to DRG Transfer Inc., a Nevada corporation and wholly owned subsidiary of the Company (“DRG”), all of the legacy assets of the Company as of April 15, 2021, comprised as of that date of the License Agreement and the name of the Company (i.e., Point of Care Nanotechnology, Inc.) and any outstanding debts of the Company generated while Dr. Guirguis operated the Company, measured as of April 15, 2021, which as of that date consisted solely of unknown contingent liabilities (which cannot be identified or quantified at this time and which are expected to be non-material or nil). The Company transferred ownership of DRG to Dr. Guirguis in exchange for the return of 520,000 (post-reverse split) shares of our common stock then held by Dr. Guirguis (The “Consideration Shares”). Dr. Guirguis has agreed to allow the Company to continue to use its existing name for an indefinite period of time.

On February 25, 2015, the Company entered into an exclusive worldwide license Agreement (the “License Agreement”) with Lamina Equities Corporation (“Lamina”), a private corporation owned by Dr. Raouf Guirguis. The License Agreement related to intellectual property for diagnosing illness in humans via a saliva test. In connection with signing the License Agreement, the Company appointed Dr. Guirguis as its Chief Executive Officer and issued to him 750,000 shares of its common stock, $0.0001 par value per share, resulting in a change of control of the Company with Dr. Guirguis becoming our majority stockholder. We did not have, however, the financial resources to pursue business development relating to the Lamina license at that time.

On April 15, 2021, Dr. Guirguis resigned from all of his positions with the Company appointing Mr. Nicholas DeVito as Chief Executive Officer, Chief Financial Officer, President, Treasurer, Secretary and sole director. In consideration for the services that Mr. DeVito would be providing to the Company, the Company issued to Mr. DeVito 1,000 shares of its super-voting, non-convertible Class A preferred stock. These shares of non-convertible Class A preferred stock voted together with the outstanding shares of our common stock as a single class and represented eighty percent (80%) of all votes entitled to be voted at any annual or special meeting of our shareholders or action by written consent of shareholders. This issuance of the 1,000 shares of Series A non-convertible preferred stock to Mr. DeVito constituted a change of control of the Company giving Mr. DeVito control of 80% of the voting power of the Company. Mr. DeVito has since surrendered those shares to us and they have now been cancelled.

The Company and Dr. Guirguis entered into a certain assignment and assumption agreement and a separate transfer agreement (together, the “Spin Off Agreements”) pursuant to which the Company transferred to DRG Transfer Inc., a Nevada corporation and wholly owned subsidiary of the Company (“DRG”), all of the legacy assets of the Company as of April 15, 2021, comprised as of that date of the License Agreement and the name of the Company (i.e., Point of Care Nanotechnology, Inc.) and any outstanding debts of the Company generated while Dr. Guirguis operated the Company, measured as of April 15, 2021, which as of that date consisted solely of unknown contingent liabilities (which cannot be identified or quantified at this time and which are expected to be non-material or nil). The Company transferred ownership of DRG to Dr. Guirguis in exchange for the return of 520,000 shares of our common stock then held by Dr. Guirguis (The “Consideration Shares”). Dr. Guirguis agreed to allow the Company to continue to use its existing name for an indefinite period of time.

On April 11, 2022, we, through our newly established, wholly owned subsidiary, Duo Sciences, Inc. (“DSI”), acquired an exclusive license from Cedoga Consulting, LLC (“Cedoga”) to distribute in the USA, Canada and Mexico, certain intellectual property of Cedoga relating to animal nutrition and animal supplements (the “Cedoga IP”). In exchange for these license rights, we agreed to issue Cedoga 300,000 shares of our common stock. Under the terms of the agreement, we will pay Cedoga royalties from sub-licensing the Cedoga IP on the following terms:

●

90% of net royalties for sales and initial payments up to $100,000,000 per calendar year;

●

95% of net royalties received for continuing sales above $100,000,000 per calendar year; and

●

90% of any lump sum up-front payment sub-licensing fees.

We also gave Cedoga an option to purchase 200,000 shares of our common stock when net sales of the Cedoga IP exceed $100,000,000.

On April 19, 2022, we, through DSI, signed an exclusive representative and sublicensing agreement with Lucy Pet Products Inc. (“Lucy”) pursuant to which Lucy has agreed to manufacture, market and distribute on our behalf pet products created from the Cedoga IP. Lucy paid us a one-time sublicensing fee of $100,000 on the signing of this agreement and will pay us royalties equal to 5% of their Net Revenue, calculated and payable quarterly. Other Income, for purposes of our agreement with Lucy, is defined as total monies received less direct cost of materials, manufacturing, packaging and delivery expenses and less excise, sales or similar taxes. We are waiting for Lucy Pets to add manufacturing capacity that will allow for additional revenues.

On May 20, 2024, we entered into an asset purchase agreement with Point of Care Nano-Technology, LLC, or “Point”, the independent, third party company established by Dr. Guirguis on completion of the Spin Off Agreements (discussed above), pursuant to which we agreed to acquire substantially all of the assets of Point for North America, consisting primarily of proprietary information and know-how for the developing and commercialization of kits to diagnose illnesses through the testing of human saliva, referred to as the “EZ Saliva” test kits, and cash in the amount of $101,400. We are currently selling EZ Saliva products to police departments, testing laboratories and private businesses to test for the presence of controlled substances.

Our Common Stock

Our common stock is currently quoted on the OTC Markets, Inc. ~~Pink~~Expert ~~tier~~Market where quotations are restricted from public viewing, under the symbol “PCNT.” ~~There~~Currently our common stock is ~~currently~~not aeligible ~~limited~~for proprietary broker-dealer quotations and the only quotes available, ~~trading~~if ~~market~~any, inreflect ~~our~~unsolicited ~~common~~customer orders. In order for broker-dealers to begin quoting our stock once again we will have to make our current information publicly available under SEC Rule 15c2-11, which we are in the process of doing. There can be no assurance that our common stock will be able to return to a full quotation status on the OTC and we cannot assure you that an active trading market in our common stock will ever develop. In the event that an active trading market commences, there can be no assurance as to the market price of our common stock, whether any trading market will provide liquidity to investors, or whether any trading market will be sustained.

Reverse Split

Executive Offices

Our principal executive office is located at 109 Ambersweet Way, Davenport FL, 33897 and our telephone number is (732) 723-7395.

Item 1A. Risk Factors

An investment in our common stock involves a high degree of risk. Before making an investment decision, you should give careful consideration to the following risk factors, in addition to the other information included in this annual report, including our financial statements and related notes, before deciding whether to invest in shares of our common stock. The occurrence of any of the adverse developments described in the following risk factors could materially and adversely harm our business, financial condition, results of operations or prospects. In that case, the trading price of our common stock could decline, and you may lose all or part of your investment .

We have a limited operational history.

We have a limited history upon which an evaluation of our prospects and future performance can be made. Our ~~proposed~~ operations are subject to all business risks associated with new enterprises. The likelihood of our success must be considered in light of the problems, expenses, difficulties, complications, and delays frequently encountered in connection with the expansion of a business operation in an emerging industry, and the continued development of advertising, promotions, and a corresponding customer base. There is a possibility that we could sustain losses in the future, and there are no assurances that we will ever operate profitably.

Our auditors have expressed substantial doubt about our ability to continue as a going concern.

As of July 31, ~~2022~~2023 and July 31, ~~2021~~2022, we had minimal cash or cash equivalents and an accumulated deficit of $120,~~275~~978,~~882~~899 and $120,~~212~~900,~~367~~882, respectively. Our audited financial statements for the years ended July 31, ~~2022~~2023 and ~~2021~~2022 were prepared using the assumption that we will continue our operations as a going concern. Our independent accountants in their audit report have expressed substantial doubt about our ability to continue as a going concern. Our operations are dependent on our ability to raise sufficient capital or complete a business ~~combination~~ combination as a result of which we become profitable. Our financial statements do not include any adjustments that may result from the outcome of this uncertainty.

There is not enough cash on hand to fund our administrative expenses and operating expenses for the next twelve months. Therefore, we may be unable to continue operations in the future as a going concern. If we cannot continue as a viable entity, our stockholders may lose some or all of their investment in our common stock.

Our operational strategy is changing to be refocused on the Life Sciences space.

We expect our business growth to be generated through ~~future~~the ~~acquisitions~~development of ~~life~~our ~~sciences~~EZ ~~assets~~Saliva business . No assurances can be made ifthat ~~any~~we ~~additional~~will ~~acquisitions~~be ~~will~~successful bein ~~consummated~~developing our EZ Saliva business.

If we do not generate sufficient cash flow from operations in the future, we may not be able to fund our product development efforts and acquisitions or fulfill our future obligations.

Our ability to generate sufficient cash flow from operations to fund our operations and business development efforts, including the potential payment of cash consideration in acquisitions and the payment of our other obligations, depends on a range of economic, competitive and business factors, many of which are outside of our control. We cannot assure you that our business will ever generate sufficient cash flow from operations, or that we will be able to raise equity or debt financings when needed or desirable. An inability to fund our operations would have a material adverse effect on our business, financial condition and results of operations. For further information, please refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations-Liquidity and Capital Resources” below.

~~Acquisitions~~Our ~~present~~Acquisition presents many risks, and we may not realize the financial and strategic goals we anticipate at the time of anthe ~~acquisition~~Acquisition.

Our growth is dependent upon our ability to ~~acquire~~develop ~~new assets~~ and tosuccessfully ~~introduce~~commercialize ~~new~~our ~~products~~acquired ~~and~~EZ ~~services~~Saliva business on a timely basis. Acquisitions, including those of high-technology companies, are inherently risky. We cannot provide any assurance ~~that~~our ~~any~~Acquisition ~~future acquisitions, if completed,~~ will be successful in helping us reach our financial and strategic goals. The risks we commonly encounter in undertaking, managing and integrating acquisitions are:

●

an uncertain revenue and earnings stream from the acquired company;

●

difficulties and delays integrating the personnel, operations, technologies, products and systems of the acquired companies;

●

the need to implement controls, procedures and policies appropriate for a public company at companies that prior to acquisition had lacked such controls, procedures and policies;

●

difficulties managing or integrating an acquired company’s technologies or lines of business;

●

potential difficulties in completing projects associated with purchased in-process research and development;

●

entry into markets in which we have no or limited direct prior experience and where competitors have stronger market positions and which are highly competitive;

●

the potential loss of key employees of the acquired company;

●

potential difficulties integrating acquired products and services into our operational framework;

●

assuming pre-existing contractual relationships of an acquired company that we would not have otherwise entered into, the termination or modification of which may be costly or disruptive to our business;

●

being subject to unfavorable revenue recognition or other accounting treatment as a result of an acquired company’s practices; and

●

intellectual property claims or disputes.

Our failure to manage growth effectively and successfully integrate our acquired assets ~~or companies~~ due to these or other factors could have a material adverse effect on our future business, results of operations and financial condition. ~~In addition, we may not have the opportunity to make suitable acquisitions on favorable terms, which could negatively impact the growth of our business.~~ We expect that other companies in our industry will compete with us towith ~~acquire~~products ~~compatible~~similar ~~assets~~to orour ~~businesses.~~EZ ~~This~~Saliva ~~competition~~test ~~could~~kits. ~~increase~~Our ~~prices for businesses and technologies that we would likely pursue, and our~~ competitors may have greater resources than we do to ~~complete~~compete in ~~these~~this ~~acquisitions~~sector.

We will require substantial funding which may not be available to us on acceptable terms, or at all. If we fail to raise the necessary capital, we may be unable to successfully implement our business plans.

We intend to ~~acquire~~expand ~~assets~~our inEZ ~~the~~Saliva ~~life sciences sector~~business. We will require capital for ~~any such acquisitions and for~~ operating expenses and capital expenditures.

We cannot be certain that funding will be available on acceptable terms, or at all. If we are unable to raise capital in sufficient amounts or on terms acceptable to us we may have to significantly delay, scale back or discontinue the development or our business, The inability to raise the required funds would significantly harm our business, financial condition and prospects.

The life-sciences industry is highly competitive and subject to rapid technological changes. As a result, we may be unable to compete successfully, which would harm our business.

The life-sciences industry is highly competitive and characterized by rapid technological change. We expect to face intense competition from other companies which have resources substantially greater than ours. This competitive disadvantage may make it extremely difficult for us to acquire commercially viable life science assets.

~~COVID~~If 19our orEZ ~~another~~Saliva ~~pandemic~~products ~~could~~are ~~greatly~~unable ~~impact~~to compete effectively with marketed tests targeting similar indications as our ~~business~~EZ Saliva products, our commercial opportunity will be reduced or eliminated.

~~While~~We weface ~~believe~~competition wegenerally ~~are~~from ~~emerging~~established pharmaceutical and biotechnology companies, as well as from ~~the~~academic ~~restrictions~~institutions, government agencies and private and public research institutions. Many of ~~COVID~~our 19competitors have significantly greater financial resources and expertise in research and development, ~~there~~manufacturing, ~~can~~preclinical betesting, noconducting ~~assurance~~clinical ~~that~~trials, obtaining regulatory approvals and marketing approved products than we ~~will~~do. ~~not~~Small or early-stage companies may also prove to be ~~impacted~~significant bycompetitors, aparticularly ~~resurgence~~through collaborative ofarrangements ~~this~~with ~~virus~~large, orestablished ~~another pandemic~~companies. ~~Any~~Our ~~such~~commercial ~~events~~opportunity ~~could~~will ~~place~~be ~~substantive~~reduced ~~restrictions~~or eliminated if our competitors develop and commercialize ~~impact~~any ontesting ~~our~~products ~~life~~that ~~sciences~~are ~~sector~~more ~~focus. In~~effective ~~such~~or aare ~~situation,~~less weexpensive ~~could~~than ~~face~~our ~~closing~~EZ ofSaliva ~~borders,~~products. ~~restricting~~These ofpotential ~~supply~~competitors compete ~~chains,~~with ~~closing~~us ofin ~~enterprises~~recruiting and ~~reductions~~retaining qualified scientific and management personnel as well as in ~~new~~acquiring ~~potential~~technologies and technology ~~life~~licenses ~~science~~complementary ~~business~~to ~~opportunities~~our programs or advantageous to our business.

We expect that our ability to compete effectively will depend upon our ability to:

successfully identify and develop key points of product differentiations from currently available tests;

successfully and rapidly complete trials and submit for and obtain all requisite regulatory approvals in a cost-effective manner;

maintain a proprietary position for our products and manufacturing processes and other related product technology;

attract and retain key personnel;

develop relationships with law enforcement, forensic and hospital testing organizations to market and sell these products; and

build an adequate sales and marketing infrastructure for our product candidates.

Because we will be competing against significantly larger companies with established track records, we will have to demonstrate that, based on experience, data, test effectiveness profiles and other factors, our products, if approved, are competitive with other products. If we are unable to compete effectively and differentiate our products from other marketed tests, we may never generate meaningful revenue.

We currently have no sales and marketing organization. If we are unable to establish a direct sales force in the United States to promote our EZ Saliva products, the commercial opportunity for our products may be diminished.

We currently have no sales and marketing organization. We will incur significant additional expenses and commit significant additional management resources to establish our sales force. We may not be able to establish these capabilities despite these additional expenditures. We will also have to compete with other pharmaceutical and biotechnology companies to recruit, hire and train sales and marketing personnel. If we elect to rely on third parties to sell our EZ Saliva products in the United States, we may receive less revenue than if we sold our products directly. In addition, although we would intend to use due diligence in monitoring their activities, we may have little or no control over the sales efforts of those third parties. In the event we are unable to develop our own sales force or collaborate with a third party to sell our EZ Saliva products, we may not be able to successfully commercialize our EZ Saliva products which would negatively impact our ability to generate revenue.

Materials necessary to manufacture our EZ Saliva products may not be available on commercially reasonable terms, or at all, which may delay the development and commercialization of our EZ Saliva products.

We will rely on the third-party manufacturers of our EZ Saliva products to purchase from third-party suppliers the materials necessary to produce test kits for sales or future trials with commercial organizations and government organizations and we will rely on such manufacturers to purchase such materials to produce the finished products for any commercial distribution of our EZ Saliva products. Suppliers may not sell these materials to our manufacturers at the time they need them to meet our required delivery schedule or on commercially reasonable terms, if at all. We do not have any control over the process or timing of the acquisition of these materials by our manufacturers. Moreover, we currently do not have any agreements for the production of these materials. If our future manufacturers are unable to obtain these materials for our test kits would be delayed, which may significantly impact our ability to generate revenue. If we or our future manufacturers are unable to purchase these materials after regulatory approval has been obtained for one of our products, the commercial launch or delivery of such product would be delayed or there would be a shortage in supply of such product, which would harm our ability to generate revenues from such product and achieve or sustain profitability.

If we are unable to adequately protect or expand our intellectual property related to our current or future products, our business prospects could be harmed.

Our success, competitive position and future revenues will depend in part on our ability to obtain and maintain trademark or patent protection, as the case may be, for our products, methods, processes and other technologies, to preserve our trade secrets, to prevent third parties from infringing on our proprietary rights and to operate without infringing the proprietary rights of third parties.

We will be able to protect our proprietary intellectual property rights from unauthorized use by third parties only to the extent that our proprietary rights are covered by valid and enforceable trademarks or patents or are effectively maintained as trade secrets. The patent position of pharmaceutical and biopharmaceutical companies involves complex legal and factual questions, and, therefore, we cannot predict with certainty whether we will be able to ultimately enforce our patents or proprietary rights. Therefore, any issued patents that we own or otherwise have intellectual property rights to may be challenged, invalidated or circumvented, and may not provide us with the protection against competitors that we anticipate. The degree of future protection for our proprietary intellectual property rights is uncertain because issued patents and other legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage.

General Economic Risks

~~The~~Our ~~Company’s~~ current and future business objectives and plan of operation are likely dependent, in large part, on the state of the general economy. Adverse changes in economic conditions may adversely affect ~~the~~our ~~Company’s~~ business objective and plan of operation. These conditions and other factors beyond ~~the~~our ~~Company’s~~ control include also, but are not limited to regulatory changes.

Risks Related to Our common stock

~~The~~Our ~~Company’s~~ shares of common stock are traded from time to time on the OTC Markets, Inc. ~~Pink~~Expert ~~Tier~~Market.

Our common stock currently trades on the OTC Markets, Inc. ~~Pink~~Expert ~~tier~~Market and is not currently eligible for proprietary broker-dealer quotations. Any quotes in our stock reflect unsolicited customer orders and are restricted from public viewing. In order for brokers to once again publish competing quotes and provide continuous market making in our stock, ~~although~~we ~~sporadically~~will need to have our publicly available information reviewed by a broker-dealer under SEC rule 15c2-11 and approved by OTC Markets, Inc. There can be no assurance that ~~there~~we will be able to successfully complete this relisting process or that there will ever be a liquid trading market for our common stock ~~following a business combination~~. In the event that a liquid trading market commences, there can be no assurance as to the market price of our common stock, whether any trading market will provide liquidity to investors, or whether any trading market will be sustained.

The application of the “penny stock” rules could adversely affect the market price of our common stock and increase your transaction costs to sell those shares.

The SEC adopted Rule 15g-9 which generally defines “penny stock” to be any equity security that has a market price (as defined) less than $5.00 per share or an exercise price of less than $5.00 per share, subject to certain exceptions. If the trading price of our common stock falls below $5.00 per share, the open-market trading of our common stock is subject to the penny stock rules, which imposes additional sales practice requirements on broker-dealers who sell to persons other than established customers and “accredited investors.” The term accredited investor” refers generally to institutions with assets in excess of $5,000,000 or individuals with a net worth in excess of $1,000,000 or annual income exceeding $200,000 or $300,000 jointly with their spouse. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document in a form prepared by the SEC, which provides information about penny stocks and the nature and level of risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction and monthly account statements showing the market value of each penny stock held in the customer’s account. The bid and offer quotations, and the broker-dealer and salesperson compensation information, must be given to the customer orally or in writing prior to effecting the transaction and must be given to the customer in writing before or with the customer’s confirmation. In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from these rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written agreement to the transaction. These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for the stock that is subject to these penny stock rules. Consequently, these penny stock rules may affect the ability of broker-dealers to trade our securities. We believe the penny stock rules discourage investor interest in and limit the marketability of our common stock.

FINRA sales practice requirements may also limit a stockholder’s ability to buy and sell our common stock.

In addition to the “penny stock” rules described above, FINRA adopted rules that require that in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative low priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer’s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA believes that there is a high probability that speculative low priced securities will not be suitable for at least some customers. FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our common stock, which may limit your ability to buy and sell our stock and have an adverse effect on the market for our shares.

Stockholders should have no expectation of any dividends.

The holders of our common stock are entitled to receive dividends when, as and if declared by our board of directors out of funds legally available therefore. To date, we have not declared or paid any cash dividends. Our board of directors does not intend to declare any dividends in the foreseeable future, but instead intends to retain all earnings, if any, for use in our business operations.

~~Our President and CEO has a no common stock equity interest and a 100% preferred stock equity interest in the Company and thus is in a position to control all actions requiring stockholder vote.~~11

~~Although~~Our ~~our~~ President and CEO, Nicholas DeVito, does not own any of our common stock, his ownership of 100% of our outstanding super-voting preferred stock give him an 80% voting control interest in the Company. This ownership interest gives Mr. DeVito controlling influence over our business, including decisions regarding mergers, consolidations and ~~the sale of all or substantially all of~~ our ~~assets,~~two ~~election~~majority of directors and other significant corporate actions. This concentration of ownership may also have the effect of discouraging, delaying or preventing a future change of control. Additionally, we have no present intention to call for an annual meeting of stockholders toare ~~elect~~in ~~new directors prior to the consummation of an asset acquisition. As~~ a ~~result,~~position our current sole officer and director will continue in office for the indefinite future. If there is an annual meeting of stockholders for any reason, the Company’s management has broad discretion regarding proposals submitted to acontrol ~~vote~~all byactions ~~shareholders~~requiring asstockholder ~~a consequence of management’s controlling equity interest~~vote. ~~Accordingly, the Company’s management will continue to exert control indefinitely.~~

After completion of the Acquisition, our two new stockholders and directors control a majority of our outstanding voting common stock. This ownership interest gives these stockholders controlling influence over our business, including decisions regarding mergers, consolidations and the sale of all or substantially all of our assets, election of directors and other significant corporate actions. This concentration of ownership may also have the effect of discouraging, delaying or preventing a future change of control. Additionally, we have no present intention to call for an annual meeting of stockholders to elect new directors. As a result, our current directors will continue in office for the indefinite future. If there is an annual meeting of stockholders for any reason, our management has broad discretion regarding proposals submitted to a vote by shareholders as a consequence of management’s controlling equity interest. Accordingly, our current board of directors and management will continue to exert control indefinitely.

Management has broad discretion in decision making.

Any person who invests in ~~the~~our ~~Company’s~~ common stock will do so without an opportunity to evaluate the specific merits or risks of any prospective asset acquisition or business combination. As a result, investors will be entirely dependent on the broad discretion and judgment of our management in connection with the selection of a prospective business opportunity. There can be no assurance that ~~determinations~~ determinations made by our management will permit us to achieve ~~the~~our ~~Company’s~~ business objectives.

Certain provisions in our certificate of incorporation and by-laws, and of Nevada law, may prevent or delay an acquisition of our company, which could decrease the trading price of our common stock.

Our certificate of incorporation, by-laws and Nevada law contain provisions that are intended to deter coercive takeover practices and inadequate takeover bids by making such practices or bids unacceptably expensive to the raider and to encourage prospective acquirers to negotiate with our board of directors rather than to attempt a hostile takeover. These provisions include, among others:

●

the inability of our stockholders to call a special meeting;

●

rules regarding how stockholders may present proposals or nominate directors for election at stockholder meetings;

●

the right of our board to issue preferred stock without stockholder approval;

●

the ability of our directors, and not stockholders, to fill vacancies on our board of directors.

Future sales and issuances of our common stock or could result in additional dilution of the percentage ownership of our stockholders and could cause our share price to fall.

We expect that significant additional capital will be needed in the future to continue our planned operations. To the extent we raise capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.

We may be at risk of securities class action litigation.

We may be at risk of securities class action litigation. In the past, life sciences, biotechnology and pharmaceutical companies have experienced significant stock price volatility, particularly when associated with binary events such as clinical trials and product approvals. If we face such litigation, it could result in substantial costs and a diversion of management’s attention and resources, which could harm our business and results in a decline in the market price of our common stock.

~~Risks Related to Our Common Stock~~12

Management identified material weaknesses in our internal controls, and failure to remediate it or any future ineffectiveness of internal controls could have a material adverse effect on ~~the~~our ~~Company’s~~ business and the price of its common stock.

Our management determined that our disclosure controls and procedures and internal controls were ineffective as of July 31, ~~2022~~2023 and ~~2021~~2022 and if they continue to be ineffective could result in material misstatements in our financial statements.

Management continues to review our internal control systems, processes and procedures for compliance with the requirements of a smaller reporting company under Section 404 of the Sarbanes-Oxley Act. Such a review resulted in identification of material weaknesses in our internal controls and a conclusion that our disclosure controls and procedures and internal control over financial reporting (“ICFR”) were ineffective as of the end of the period covered by this Report.

A “material weakness” is a deficiency, or a combination of deficiencies, in ICFR, such that there is a reasonable possibility that a material misstatement of ~~the~~our ~~company’s~~ annual or interim financial statements will not be prevented or detected on a timely basis. We plan to take measures to remediate these deficiencies, such as providing additional training to our accounting staff in US GAAP. However, the implementation of these measures may not fully address the control deficiencies in our ICFR. Our failure to address any control deficiency could result in inaccuracies in our financial statements and could also impair our ability to comply with applicable financial reporting requirements and related regulatory filings on a timely basis. Moreover, effective ICFR is important to prevent fraud. As a result, our business, financial condition, results of operations and prospects, as well as the trading price of our shares, may be negatively impacted by a failure to accurately report financial results.

The material weaknesses and other matters impacting ~~the~~our ~~Company’s~~ internal controls may cause it to be unable to report its financial information on a timely basis and thereby subject it to adverse regulatory consequences, including sanctions by the SEC or violations of applicable stock exchange or quotation service listing rules. There could also be a negative reaction in the financial markets due to a loss of investor confidence in the Company and the reliability of its financial statements. Confidence in the reliability of ~~the Company’s~~our financial statements may suffer due to ~~the~~our ~~Company’s~~ reporting of material weaknesses in its internal controls over financial reporting. This could materially adversely affect the Company and lead to a decline in the price of its common stock.

If we fail to comply with the rules under the Sarbanes-Oxley Act of 2002 related to disclosure controls and procedures, or, if we discover material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly and raising capital could be more difficult.

If we fail to comply with the rules under the Sarbanes-Oxley Act of 2002 related to disclosure controls and procedures, or, if we discover additional material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly and raising capital could be more difficult. Moreover, effective internal controls are necessary for us to produce reliable financial reports and are important to helping prevent financial fraud. If we cannot provide reliable financial reports or prevent fraud, our business and operating results could be harmed, investors could lose confidence in our reported financial information, and the trading price of our common stock could drop significantly. In addition, we cannot be certain that additional material weaknesses or significant deficiencies in our internal controls will not be discovered in the future.

Our common stock price could continue to be volatile and you could lose the value of your investment.

Our stock price has been volatile and has fluctuated significantly in the past. The market price of our common stock could continue to be volatile and could fluctuate widely in price in response to various factors, many of which are beyond our control, including: technological innovations or new products and services by us or our competitors; additions or departures of key personnel; sales of our common stock; our ability to integrate operations, technology, products and services; our ability to execute our business plan; operating results below expectations; loss of any strategic relationships; industry developments; economic and other external factors; and period-to-period fluctuations in our financial results. Because we have a very limited operating history with no revenues to date, you may consider any one of these factors to be material. Our stock price may fluctuate widely as a result of any of the above. In addition, the securities markets have from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. These market fluctuations may also materially and adversely affect the market price of our common stock. Your investment in our stock could lose some or all of its value.

If securities or industry analysts do not publish research or reports about our business, or if they change their recommendations regarding our stock adversely, our stock price and trading volume could decline.

The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. We do not currently have and may never obtain research coverage by industry or financial analysts. If no or few analysts commence coverage of us, the trading price of our stock would likely decrease. Even if we do obtain analyst coverage, if one or more of the analysts who cover us downgrade our stock, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline

Item 1B. Unresolved Staff Comments

None.

Item 1C. Cybersecurity

The Company, whether at the board of directors or management level, does not currently have any processes in place for assessing, identifying, and managing material risks from cybersecurity threats.

Item 2. Properties

The Company does not own or rent any properties. Our mailing address is a post-office box located at 109 Ambersweet Way, Davenport, FL 33897 and our telephone number is (732) 723-7395. We are currently conducting our business operations out of the residence of our CEO, Mr. DeVito, at no charge to us.

Item 3. Legal Proceedings

We know of no material, active or pending legal proceedings against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

Item 4. Mine Safety Disclosure

Not applicable.

PART II

Item 5. Market for Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Market Information

Our ~~Common~~common ~~Stock~~stock is currently quoted on the OTC Markets, Inc. ~~Pink~~Expert ~~tier~~Market where quotations are restricted from public viewing, under the symbol “PCNT.” ~~Any~~Currently ~~over~~our common stock is not eligible for proprietary broker-dealer quotations and the only quotes available, if any, reflect unsolicited customer orders. In order for broker-~~counter~~dealers ~~market~~to ~~quotations~~begin quoting our stock once again we will have to make our current information publicly available under SEC Rule 15c2-11, which we are in the process of doing. There can be no assurance that our common stock will be able to return to a full quotation status on the OTC’s ~~Pink~~and ~~tier~~we ~~reflect~~cannot ~~inter-dealer~~assure ~~prices~~you that an active trading market in our common stock will ever develop. In the event that an active trading market commences, ~~without~~there ~~retail~~can ~~mark-up~~be no assurance as to the market price of our common stock, ~~mark-down~~whether any trading market will provide liquidity to investors, or ~~commission~~whether ~~and~~any ~~may~~trading ~~not~~market ~~necessarily~~will ~~represent actual~~be ~~transactions~~sustained.

Description of Our Common Stock

We are authorized to issue 100,000,000 shares, par value $0.0001 per share, of common stock, of which ~~940~~72,690,621 ~~(post-reverse split)~~ shares were issued and outstanding as of October 2529, ~~2022~~2024 . Holders of common stock are entitled to one vote per share on each matter submitted to to a vote at any meeting of stockholders. Shares of common stock do not carry cumulative voting rights and, therefore, holders of a majority of the outstanding shares of common stock will be able to elect the entire Board of Directors, and, if they do so, minority stockholders would not be able to elect any members to the Board of Directors. Our Board of Directors has authority, without action by the stockholders, to issue all or any portion of the authorized but unissued shares of common stock, which would reduce the percentage ownership of the stockholders and which may dilute the book value of the common stock. Stockholders have no pre-emptive rights to acquire additional shares of common stock. The common stock is not subject to redemption and carries no subscription or conversion rights. In the event of liquidation, the shares of common stock are entitled to share equally in corporate assets after satisfaction of all liabilities. The shares of common stock, when issued, will be fully paid and non-assessable.

Holders of common stock are entitled to receive dividends as our board of directors may from time to time declare out of funds legally available for the payment of dividends. We have not paid dividends on common stock and do not anticipate that we will pay dividends in the foreseeable future.

All shares of common stock now outstanding are duly authorized, fully paid and non-assessable.

Preferred Stock

We are authorized to issue up to 10,000,000 “blank check” shares of preferred stock, par value $0.0001 per share, with all designations, rights and privileges as our board of directors may decide, from time to time, without stockholder approval. As of October 2529, ~~2022~~2024, ~~there~~the ~~are~~Company ~~1,000~~had no shares of our preferred stock issued or outstanding.

On April 14, 2021, our board of directors agreed to create, and issued, 1,000 shares of series A non-convertible preferred stock to Nicholas P. DeVito. The series A non-convertible preferred stock was designated to carry voting rights equal to eighty percent (80%) of all of the votes entitled to be voted at any annual or special meeting of the shareholders of the Company or action by written consent of the shareholders.

In connection with the Acquisition, Mr. DeVito surrendered to the Company for cancellation, the Preferred Stock and received, in exchange, 5,000,000 shares of our common stock on May 21, 2024.

Transfer Agent

Our transfer agent is ~~Vstock Transfer~~ClearTrust, LLC, located at 1816540 ~~Lafayette~~Pointe ~~Pl,~~Village ~~Woodmere~~Dr, NYLutz ~~11598~~Fla, telephone: (~~212~~813) ~~828~~235-~~8436~~4490.

Holders

As of October 2529, ~~2022~~2024, we had 3746 record holders of our common stock (not including beneficial owners who hold shares at broker/dealers in “street name”).

Dividend Policy

While there are no restrictions that limit our ability to pay dividends, we have not paid, and do not currently intend to pay cash dividends on our common stock in the foreseeable future. Our policy is to retain all earnings, if any, to provide funds for the operation and expansion of our business. The declaration of dividends, if any, will be subject to the discretion of our Board of Directors, which may consider such factors as our results of operations, financial condition, capital needs and acquisition strategy, among others.

Issuer Purchases of Equity Securities

None

Item 6. Selected Financial Data.

Not applicable

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with our audited financial statements and the notes to those financial statements that are included elsewhere in this Form 10-K. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth under the “Risk Factors”, “Cautionary Notice Regarding Forward-Looking Statements” and “Description of Business” sections and elsewhere in this annual report. We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” “predict,” and similar expressions to identify forward-looking statements. Although we believe the expectations expressed in these forward-looking statements are based on reasonable assumptions within the bound of our knowledge of our business, our actual results could differ materially from those discussed in these statements. Factors that could contribute to such differences include, but are not limited to, those discussed in the Risk Factors” section of this annual report. We undertake no obligation to update publicly any forward-looking statements for any reason even if new information becomes available or other events occur in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results. Readers are urged to carefully review and consider the various disclosures made throughout the entirety of this annual report, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations, and prospects.

Overview

On February 25, 2015, the Company entered into the License Agreement with Lamina relating to intellectual property for diagnosing illness in humans via a saliva test. During the past few years, the Company did not have the financial resources to pursue business development relating to the Lamina license and this business was discontinued and split off.

~~The~~On ~~Company’s plan of operation over the next 12 months is to seek and acquire new business assets in the life sciences industry and begin operations with these new assets. To that end, on~~ April 11, 2022, we, through our newly established, wholly owned subsidiary, DSI, acquired an exclusive license from Cedoga to distribute in the USA, Canada and Mexico, certain intellectual property of Cedoga relating to animal nutrition and animal supplements. On April 19, 2022, we, through DSI, signed an exclusive representative and sublicensing agreement with Lucy Pet Products Inc. pursuant to which Lucy has agreed to manufacture, market and distribute on our behalf pet products created from the Cedoga IP. There can be no assurance that we will be successful marketing the Cedoga IP or that Lucy or other sublicensees of the Cedoga IP will be successful in their business development efforts.

13On May 20, 2024, we entered into an asset purchase agreement with Point of Care Nano-Technology, LLC pursuant to which we agreed to acquire substantially all of the assets of Point for North America, consisting primarily of proprietary information and know-how for the developing and commercialization of kits to diagnose illnesses through the testing of human saliva, referred to as the “EZ Saliva” test kits, and cash in the amount of $101,400. We are currently selling EZ Saliva testing products to police departments, testing laboratories and private businesses to test for the presence of controlled substances.

Our plan of operation for the next 12 months is to build our EZ Saliva business through traditional direct sales and marketing efforts to police departments and lab test companies in North America.

Additionally, we can make no guarantees that we will be successful in achieving any of our new operational objectives.

Results of Operations

Fiscal Year ended July 31, ~~2022~~2023 compared to the Fiscal Year ended July 3031, ~~2021~~2022

Revenues

For the ~~year~~years ended July 31, ~~2022~~2023, we generated $~~100,000~~0 of revenue from product licenses as compared to $0 revenue of any kind for year ending July 31, ~~2021~~2022.

Cost of Goods Sold

For the years ended July 31, ~~2022~~2023 and July 31, ~~2021~~2022, we did not incur any cost of goods sold expenses from product licenses, maintenance, services or other expenses.

Operating Expenses

For the year ended July 31, ~~2022~~2023, we ~~incurred~~did ~~$90,000~~not ofincur any operating expenses from product licenses, and for the year ending July 31, ~~2021~~2022, we incurred $0 ~~did~~of ~~not incur any~~ operating expenses from product licenses. We incurred administrative expenses of $7378,~~515~~017 for the year ended July 31, ~~2022~~2023 and $773,~~500~~515 for the year ended July 31, ~~2021~~2022.

Net Other Income (Expense)

For the years ended July 31, ~~2021~~2023 and July 31, ~~2020~~2022, we incurred net other income (expense) of -0- and ($615,000) respectively. In 2022 we ~~did~~received ~~not~~$100,000 ~~receive~~of ~~any~~royalty income orfrom ~~incur~~Lucy ~~any~~Pets which was offset with $90,000 of other expense ~~from~~due to Cedoga. The remaining other ~~sources~~expense was generated from a license impairment.

Liquidity & Capital Resources

At July 31, ~~2022~~2023, we had $~~3,198~~498 in cash, compared to $03,198 at July 31, ~~2021~~2022. At July 31, ~~2022~~2023, our accumulated stockholders’ deficit was $120,~~275~~978,~~882~~899 compared to $120,~~212~~900,~~367~~882 at July 31, ~~2021~~2022. There is substantial doubt as to our ability to continue as a going concern.

We have had no net positive cash flow for the two years ended July 31, ~~2022~~2023 and ~~2021~~2022. In the future, our cash flow will depend on the timely and successful market entry of our expected strategic offerings and our ability to raise capital.

~~There were no equity transactions in the fiscal year ended July 31, 2021.~~ In 2022, we received into treasury 520,000 shares of common stock in connection with our settlement agreement with the previous director. We are required to issue 300,000 ~~(post-reverse split)~~ shares of our common stock for acquiring a license agreement. In 2023 we cancelled the 520,000 shares received from a former Director in accordance with our settlement agreement. In addition, we raised $20,000 from one investor and we issued him 150,000 shares of Common Stock on October 29, 2024..

Especially for strategic offerings for paradigm shifting technologies, our management’s budget plan is based on a series of assumptions regarding the amount of capital needed to pursue regulatory approval, market acceptance, readiness and pricing for any new life science product we may acquire. While management’s assumptions are based on market research, assumptions bear the risk of being incorrect and may result in a delay in projects, delays in regulatory approvals and consequently a delay or a reduction in the related strategic offerings. In case these delays have an impact on our liquidity and therefore our ability to support our operations with the necessary cash flow, we expect to depend on our ability to generate cash flow from other resources, such as debt financing from related or independent resources or as equity financing from existing stockholders or through the stock market. There can be no assurances, however, that we will be successful in raising required funding on terms acceptable to us, if at all.

We issued 1,000 shares of series A non-convertible preferred stock to Mr. Nicholas DeVito on August 2, 2021 that gives him 80% voting control of the company.

Plan of Operations

During the remainder of our fiscal year ending July 31, ~~2023~~2024 and for the following 12 months, weour ~~will~~plan ~~seek~~of operation is to ~~acquire~~build ~~additional~~our ~~strategic~~EZ ~~assets~~Saliva business inthrough ~~the~~traditional ~~life~~direct ~~sciences~~sales ~~space~~and marketing efforts to police departments and lab test companies in North America. We will need to seek external sources of capital for financing ~~future~~this ~~projects~~business development. These sources may also provide the necessary funds to to support our ongoing working capital needs. There can be no assurances, however, that we will be able to obtain additional funds or ~~that~~ that such funds will be sufficient to permit us to successfully implement our intended business strategy. In the event we are not able to to raise funds, our management will have to postpone the ~~acquisition~~further development of ~~any~~our ~~new~~EZ ~~assets~~Saliva ~~until the required financing becomes available~~product. Additionally, our management believes we will need to raise money to support our standard operations for the remainder of the current fiscal year ending July 31, ~~2023~~2024 and for the following 12 months.

14Our cash balance as reported in our financial statements is not sufficient to fund our growth plan for any period of time. In order to fully implement our plan of operations for the next 12-month period, we will need to raise a significant amount of capital through future offerings. After the next 12-month period, we most likely will need to raise additional financing as well. The discussion below is based on the assumption that we will be able to raise significant capital in the remainder of our fiscal year ending July 31, 2024. We do not currently have any arrangements for any such financing and there can be no assurances that we will be able to raise the required capital on acceptable terms, if at all.

Our cash balance as reported in our financial statements is not sufficient to fund our growth plan for any period of time. In order to fully implement our plan of operations for the next 12-month period, we will need to raise a significant amount of capital through future offerings. After the next 12-month period, we most likely will need to raise additional financing as well. The discussion below is based on the assumption that we will be able to raise significant capital in the remainder of our fiscal year ending July 31, 2023. We do not currently have any arrangements for any such financing and there can be no assurances that we will be able to raise the required capital on acceptable terms, if at all.17

We have generated minimal revenues to date and, although we expect to raise significant capital in the future, there can be no assurances that we will be successful in these endeavors. We believe that the actions presently being taken to further implement our business plan and generate revenues will provide the opportunity for us to develop into a successful business operation.

We can provide no assurances, however, that we will be able to successfully acquire additional assets or raise sufficient funds in the next six months or longer to continue to execute our plans, to reach or to develop, offer and generate revenues from any of our designated business activities and development actions. Also, we cannot assure you that we will be able to raise additional capital or debt as and when needed on acceptable terms if at all.

Additional Cash Requirements

WeIn addition to business development expenses, we expect to incur additional administrative expenses during the next 12 months. We estimate that we will need the following amounts during the next 12 months to cover the indicated administrative expenses:

Category	Estimated Amount
Legal		50,000
Accounting		50,000
OTC Listing Fees		10,000
Travel		5,000
Miscellaneous		5,000
TOTAL	$	120,000

This capital will be used to build out our corporate infrastructure, to provide for the payment of advisory and accounting services, legal, and anticipated ~~up-listing~~relisting fees for the OTC Markets, Inc. ~~QB tier.~~ However, there can be no assurance that we will qualify for ~~uplisting to~~relisting ~~the OTC QB tier or that our application~~ to the OTC ~~QB will be approved~~Market. The table above does not include a line item for funds required to ~~acquire~~expend ordeveloping ~~develop~~our ~~life~~EZ ~~science~~Saliva ~~assets~~business. Any such funds will be in amounts in addition to those listed in the table.

Required funds may be raised through equity financing, debt financing, or other sources, which may result in further dilution in the equity ownership of our shares. There is no assurance that we will be able to generate operations at a level sufficient for an investor to obtain a return on their investment in our common stock, or that we will be able to raise sufficient capital required to implement our business plan on acceptable terms, if at all. Even if we are successful in raising sufficient capital to implement our business plan, we may continue to be unprofitable.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America, the more significant of which are as follows:

Consolidation

The accompanying consolidated financial statement include the accounts of the Company and its wholly owned subsidiary Duo Sciences Inc. (“DSI”)

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Changes in estimates are recognized in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available to management. Actual results could differ from those estimates.

Financial Instruments

Financial instruments consist of cash and accounts payable and accrued liabilities. The carrying amounts of the financial instruments approximate their fair values due to their relatively short-term nature of the underlying terms are consistent with market terms. As of the financial statement date, the Company does not hold any derivate financial instruments. Financial assets and liabilities are measured upon first recognition and reviewed at the financial statement date. Changes in fair value are recognized through profit and loss. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest or credit risks arising from these financial instruments.

Fair Value Measurements

The Company follows FASB Codification topic (“ASC”) 820, Fair Value Measurements and Disclosures, for all financial instruments and non-financial instruments accounted for at fair value on a recurring basis. This new accounting standard establishes a single definition of fair value and a framework for measuring fair value, sets out a fair value hierarchy to be used to classify the source of information used in fair value measurement and expands disclosures about fair value measurements required under other accounting pronouncements. It does not change existing guidance as to whether or not an instrument is carried at fair value. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, the Company considers the principal or most advantageous market in which the Company would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions and credit risk.

The Company has adopted FASB ASC 825, Financial Instruments, which allows companies to choose to measure eligible financial instruments and certain other items at fair value that are not required to be measured at fair value. The Company has not elected the fair value option for any eligible financial instruments.

An asset or liability’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Availability of observable inputs can vary and is affected by a variety of factors. The Company uses judgment in determining fair value of assets and liabilities, and Level 3 assets and liabilities involve greater judgment than Level 1 and Level 2 assets or liabilities.

Revenue Recognition

Effective August 1, 2018, the Company adopted ASC, Topic 606, “Revenue from Contracts with Customers”, using the modified retrospective transition method as permissible for all contracts not yet completed as of August 1, 2018. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.

Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contracts) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.

Income Taxes

The Company accounts for income taxes under FASB ASC Topic 740, Income Taxes (“ASC Topic 740”). Under ASC Topic 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. As the Company has yet to produce positive cash flows from operations, no deferred tax asset or income taxes have been recorded in the financial statements.

Comprehensive Income (Loss)

The Company adopted FASB ASC 220, Reporting Comprehensive Income, which establishes standards for the reporting and display of comprehensive income and its components in the financial statements. Comprehensive income consists of net income and other gains and losses affecting stockholder’s equity that are excluded from net income, such as unrealized gains and losses on investments available for sale, foreign currency translation gains and losses and minimum pension liability. Since inception, the Company has not had any comprehensive income / loss.

Net Income (Loss) per Common Share

FASB ASC 260, Earnings per share, requires dual presentation of basic and diluted earnings per share (EPS) with a reconciliation of the numerator and denominator of the EPS computations. Basic earnings per share amounts are based on the weighted average shares of common stock outstanding. If applicable, diluted earnings per share would assume the conversion, exercise or issuance of all potential common stock instruments such as options, warrants and convertible securities, unless the effect is to reduce a loss or increase earnings per share. Diluted net income (loss) per share on the potential exercise of the equity-based financial instruments is not presented where anti-dilutive. Accordingly, although the diluted weighted average number of common stock outstanding is disclosed on the statements of operation, the calculated net loss per share is the same for bother basic and diluted as both are based on the basic weighted average of common stock outstanding. There were no adjustments required to net income for the period presented in the computation of diluted earnings per share.

Segment Reporting

FASB ASC 820, “Segments Reporting,” establishes standards for reporting information about operating segments on a basis consistent with ~~the~~our ~~Company’s~~ internal organization structure as well as information about geographical areas, business segments and major customers in financial statements. The Company currently operates in one principal business segment.

Intangible assets

Intangible asset are non-monetary identifiable assets, controlled by the Company that will produce future economic benefits, based on reasonable and supportable assumptions about conditions that will exist over the life of the asset. An intangible asset that does not meet these attributes will be recognized as an expense when it is incurred. Intangible assets that do, are capitalized and initially measure at cost. Those with a determinable life will be amortized on a systematic basis over their future economic life. Those with an indefinite useful life shall not be amortized until its useful life is determined to be longer than indefinite. An intangible asset subject to amortization shall be periodically reviewed for impairment . We recorded an impairment of $625,000 on the Lucy Pets license on July 31, 2022 to reflect our internal analysis of future discounted cash flows. A recoverability test will be performed and, if applicable, unscheduled amortization is considered.

The license agreements has been capitalized, recorded at cost and amortized over its estimated useful life of ten years. Amortization has been determined based on a pro rata basis over the expected cash flows.

Non-cash transactions

The Company follows FASB ASC 845 then recording non-cash transactions. The value of the asset received should be based on the value of the assets surrendered. However, where that value is difficult to determine, then the value could be based on the asset received, provided it is more clearly evident than the value of the asset surrendered.

Related Parties

The Company adopted FASB ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

Recent Accounting Pronouncements

The Company adopts new pronouncements relating to generally accepted accounting principles applicable to the Company as they are issued, which may be in advance of their effective date. The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on ~~the~~our ~~Company’s~~ results of operations, financial position, or cash flow.

The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America, the more significant of which are as follows:

Item 7A. Quantitative and Qualitative Disclosure about Market Risk.

Nor applicable

Item 8. Financial Statements and Supplementary Data

Our audited financial statements and related financial statement schedule, together with the report of independent registered public accounting firm, appear at pages F-1 through F-11 of this Annual Report on Form 10-K for the year ended July 31, ~~2022~~2023.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Not applicable.

Item 9A. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As of July 31, ~~2022~~2023, our management, with the participation of our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial and accounting officer), Mr. Nicholas P. DeVito, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15(b) promulgated under the Securities Exchange Act. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of July 31, ~~2022~~2023, our disclosure controls and procedures were not effective in ensuring that the information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, including ensuring that such material information is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Management’s Annual Report on Internal Control over Financial Reporting (ICFR)

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (“ICFR”), as such term is defined in Rule 13a-15(f) of the Exchange Act. ICFR refers to the process designed by, or under the supervision of, our Interim Chief Executive Officer and Chief Financial Officer, and effected by our Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles (“GAAP”), and includes those policies and procedures that:

(i)

Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;

(ii)

Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and

(iii) Provide reasonable assurance regarding prevention or timely detection of an unauthorized acquisition, use or disposition of ~~the~~our ~~Company’s~~ assets that could have a material effect on the financial statements.

Because of its inherent limitations, ICFR may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

A material weakness is a deficiency, or a combination of deficiencies, in ICFR, such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis.

Management has evaluated the effectiveness of ~~the~~our ~~Company’s~~ ICFR as of July 31, 2022 and 2023. Management based its assessment on the framework ~~set~~ set forth in COSO’s Internal Control – Integrated Framework (1992) in conjunction with SEC Release No. 33-8810 entitled “Commission Guidance Regarding Management’s Report on Internal Control Over Financial Reporting Under Section 13(a) or 15(d) of the Securities and Exchange Commission” (17 CFR PART 241; Effective June 27, 2007).

18Because of the material weaknesses described below, management concluded that our ICFR was not effective as of July 31, 2023:

~~Because of~~● ~~the~~Our ~~material~~lack ~~weaknesses~~of ~~described~~sufficient ~~below,~~accounting ~~management~~personnel ~~concluded~~with ~~that~~ the ~~Company’s~~requisite ~~ICFR~~knowledge ~~was~~of ~~not~~GAAP ~~effective~~and asthe offinancial ~~July~~reporting ~~31,~~requirements ~~2022:~~of the SEC.

● The Company’s lack of sufficient accounting personnel with the requisite knowledge of GAAP and the financial reporting requirements of the SEC.

●

Lack of segregation of duties of internal accounting and SEC reporting departments.

We plan to take measures to remediate these deficiencies, such as hiring additional qualified personnel and providing additional training to our accounting staff in US GAAP, once we have the necessary financial resources. However, the implementation of these measures may not fully address the control deficiencies in our ICFR. Our failure to address any control deficiency could result in inaccuracies in our financial statements and could also impair our ability to comply with applicable financial reporting requirements and related regulatory filings on a timely basis. Moreover, effective ICFR is important to prevent fraud. As a result, our business, financial condition, results of operations and prospects, as well as the trading price of our shares, may be negatively impacted by a failure to accurately report financial results.

Changes in Internal Control Over Financial Reporting (ICFR)

During the fourth quarter ended July 31, ~~2022~~2023, there were no changes in our ICFR that have materially affected, or are reasonably likely to materially affect, our ICFR.

This annual report does not include an attestation report of our registered public accounting firm regarding ICFR. Management’s report was not subject to attestation by our registered public accounting firm pursuant to temporary rules of the SEC that permit us to provide only management’s report in this annual report.

Item 9B. Other Information.

Subsequent Events:

On ~~August~~May 2420, ~~2022~~2024, Wewe ~~completed~~entered ainto ~~financing with~~ an ~~investor~~asset ~~for~~purchase ~~$10,000~~agreement inwith ~~exchange~~Point ~~for~~of ~~Units~~Care ~~consisting~~Nano-Technology, ofLLC (i“Point”), ~~one~~an ~~share~~unrelated ~~of our common~~company ~~stock~~established ~~for~~by $0Dr.10 ~~per~~Guirguis ~~share,~~as ~~(ii)~~a ~~one~~result ~~option~~of tothe ~~purchase~~Spin ~~one~~Off ~~share~~Agreements, ofpursuant ~~our~~to ~~common~~which ~~stock~~it ~~for~~agreed ~~$0.20~~to ~~per~~acquire ~~share~~substantially ~~upon~~all ~~our signing~~ of athe ~~letter~~North American assets of ~~intent~~Point, ~~with~~consisting aprimarily ~~third~~of ~~party~~proprietary information and ~~(iii)~~know-how ~~one~~for ~~option~~the developing and commercialization of kits to ~~purchase~~diagnose ~~one~~illnesses ~~share~~through the testing of ~~our~~human ~~common~~saliva, ~~Stock~~referred ~~for~~to ~~$0.30~~as ~~per~~the ~~share~~“EZ ~~upon~~Saliva” ~~our~~test ~~signing~~kits, ofand ~~an agreement~~cash ~~with~~in athe ~~third~~amount of ~~party~~$101,400.

19In exchange for the Assets, we issued to Point and its designees 66,000,000 restricted shares of our common stock.

Upon the closing of the Acquisition, which effected a change of control of the Company, Dr. Raouf Guirguis, the controlling member of Point, became a director of the Company and Chief Scientific Officer. Dr. Guirguis also acquired, directly and indirectly, 34,596,800 of the Consideration Shares, or approximately 48.4% of the shares of our common stock outstanding after completion of the Acquisition. Mr. Nathan Keele, an associate of Dr. Guirguis and responsible for marketing efforts at Point, also was appointed to the board of directors of the Company. Mr. Keele will continue his marketing efforts at the Company. Mr. Keele acquired 18,903,200 of the Consideration Shares, or approximately 26.5% of the shares of our common stock outstanding after completion of the Acquisition.

Nicholas DeVito, our controlling stockholder prior to the Acquisition through the 1,000 shares of super-majority class A preferred stock of the Company that he held and through which he exercised eighty percent (80%) voting control over the Company, surrendered to us for cancellation the Preferred Stock and received, in exchange, 5,000,000 shares of our common stock. Mr. DeVito will retain his positions as Chief Executive Officer, Chief Financial Officer, Treasurer and Secretary of the Company as well as his status as a member of our board of directors.

The shares of Company common stock being issued in connection with the Acquisition (as described above) were issued in accordance with a private placement exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, and are considered “restricted securities.”

In connection with the Acquisition, the Company entered into a license agreement with Zeus Diagnostics, LLC, a Delaware limited liability company controlled by Dr. Guirguis, pursuant to which we acquired an exclusive, in perpetuity, license, with a right to sublicense, in the Territory (Canada, the United States and Mexico) to the “Zeus Know-How” which consists of all information related to the manufacture and commercialization of saliva tests derived from patents owned by Zeus. The Company paid Zeus a one-time, non-refundable up-front cash fee of $35,000 (which is creditable against other payments due) and will pay Zeus a royalty on “Net Sales” (as defined in the License Agreement) of Seven and One-Half Percent (7.5%) during each calendar quarter.

Following the closing of the Acquisition, our business has begun to focus on the EZ Saliva product commercialization activity previously carried on by Point.

On September 20, 2024, we issued 1,270,000 shares of our common stock to three investors and raised $30,000.

On May 30, 2024, we engaged and executed an agreement with Fruci & Associates II, PLLC as our new independent accountant for the fiscal years ended July 31, 2023 and 2022.

PART III

Item 10. Directors, Executive Officers and Corporate Governance

The table below sets forth the names, title and ages of our current directors and executive officers. Directors hold office until the next annual meeting of the stockholders or until their successors have been elected and qualified. Executive officers serve at the pleasure of our board of directors and may be removed with or without cause at any time, subject to contractual obligations between our executive officer and the Company, if any.

Name	Age	Position and Offices Held	Director Since
Nicholas DeVito	5961	Chief Executive Officer, Chief Financial Officer, President, Treasurer, Secretary and Director	April 15, 2021
Dr. Raouf Guirguis	72	Chief Science Officer, Director	May 21, 2024
Mr. Nathan Keele	37	Director	May 21, 2024

Business Experience:

Nicholas P. DeVito. Mr. DeVito has 3537 years of experience in finance, engineering and operations in a variety of industries including oil & gas, telecommunications, alternative energy, manufacturing and consumer products. He is currently serving as Senior Director of Accounts at Synchronoss Technologies where he has held that position since 2016. Mr. DeVito has served as Chief Executive Officer (2018) and Interim Chief Executive Officer (2019 to 2020)) of Marizyme, Inc. (OTCQB: MRZM). From May 7, 2018 until his resignation ~~from~~ from this position on September 12, 2018, he served on the Marizyme board of directors as Chairman. From December 2009 to December 2013, he he served as Chief Operating Officer of Xtreme Oil & Gas Inc. (OTC: XTOG), successfully reorganizing that company and completing ~~the~~ the public filings to enable the company to begin public trading. Mr. DeVito has served as VP of Business Development for Tellium, Inc., now known as DZS Inc. (NASDAQ: ZHNE), a telecommunications equipment manufacturer that sold optical switching products and completed an IPO in 2001. Mr. DeVito has provided operations and sales consulting services to several public and private companies. He was employed at AT&T and Bell Laboratories from June 1985 to August 1998. He has a BSEE and MSEE from Columbia University and an MBA in Management from New York University. Mr. DeVito has not held any other public company director positions in the past five years.

~~Key~~Dr. ~~Attributes,~~Raouf ~~Experience~~Guirguis has been the Chairman and ~~Skills:~~Chief MrExecutive Officer of Lamina Equities Corporation since 2001. ~~DeVito~~He ~~brings~~currently ~~his~~serves as ~~financial~~Director and Chief Science officer at Point of Care Nano Technology, ~~operational~~Inc and ~~acquisitions~~managing ~~experience~~member of Point and BioPharmatech, LLC, companies he controls. From 2005 to 2010, he was the ~~Board~~President ~~along~~of ~~with his~~Diplomatic ~~leadership~~Language ~~and~~Services, ~~investor~~LLC. ~~relations~~Since ~~skills~~2011, Dr. HeGuirguis has been the ~~ability~~President of toConverting ~~establish~~Biophile aLaboratories, ~~vision~~LLC. ~~and~~His ~~manage~~involvement with the ~~execution~~companies ranged from the conception of the business ~~plans~~plan to technology packaging, mergers and acquisitions, and business development. Dr. Guirguis served as Pathology Fellow, National Cancer Institute, ~~growth~~NIH ~~goals~~(1984-1989) and was a Georgetown University Scholar (1985-1988). He holds an M.D. as well as an M.S., ~~creating~~Studies ~~value~~in ~~for~~General ~~stockholders~~Medical Practice, from the University of Alexandria, Egypt. He also holds an M.S. in Biomedical Engineering and ~~achieving~~a ~~successful~~Ph.D. ~~exits~~in Physiology and Biophysics from Georgetown University.

From February 2015 to April 2021, Dr. Guirguis had been the Chief Executive Officer and majority stockholder of the Company during which period the “Zeus Know-How” was owned by the Company. Following Dr. Guirguis’ departure in 2021, the Zeus Know-How was spun out to a new company wholly owned by Dr. Guirguis.

Mr. Nathan Keele has been the founder and CEO of Keele Medical since 2020. He served as Regional Leader at US Health Advisors from 2018 to 2020, where he honed his skills in team building and leadership. His entrepreneurial journey continued as he co-founded a fully accredited clinical diagnostic laboratory, Vanguard Laboratories in 2021, serving as CEO there until 2023. Mr. Keele received his associate’s degree in Psychology from Utah Valley University, 2017.

Family Relationships

There are no family relationships between or among any of our current directors, executive officers or persons nominated or charged by the Company to become directors or executive officers. There are no family relationships among our executive officers and directors and the executive officers and directors of our direct and indirect subsidiaries.

Involvement in Certain Legal Proceedings

None of the directors or executive officers has, during the past ten years:

(a)

Had any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time;

(b)

Been convicted in a criminal proceeding or subject to a pending criminal proceeding;

(c)

Been subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities, futures, commodities or banking activities; or

(d)

Been found by a court of competent jurisdiction (in a civil action), the SEC or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated.

Code of Conduct

We have not adopted a Code of Conduct.

Changes in Officers and Directors

Mr. DeVito was appointed the Chairman of our board of directors on April 15, ~~2022~~2021 and Chief Executive Officer, President, Secretary and Treasurer on April 15, 2021. Dr. Raouf Guirguis and Mr. Nathan Keele were appointed to ~~fill~~our ~~the~~board ~~vacancies~~of ~~created~~directors byon May 20, 2024 as part of the ~~resignation~~acquisition of ~~Dr.~~the ~~Raouf~~licenses ~~Guirguis~~for ~~from~~the ~~these~~EZ ~~positions~~Saliva technologies.

Compliance with Section 16(a) of the Securities Exchange Act of 1934

Section 16(a) of the Exchange Act requires our executive officers and directors and persons who own more than 10% of a registered class of our equity securities to file with the SEC initial statements of beneficial ownership, reports of changes in ownership and annual reports concerning their ownership of our Common Stock and other equity securities, on Forms 3, 4 and 5 respectively. Executive officers, directors and greater than 10% shareholders are required by the SEC regulations to furnish us with copies of all Section 16(a) reports that they file.

Based solely on our review, our then sole officer and director failed to file his Section 16(a) forms on a timely basis in ~~2022~~2023.

Item 11. Executive Compensation

EXECUTIVE COMPENSATION

The following table sets forth all plan and non-plan compensation for the last two completed fiscal years paid to all individuals who served as ~~the~~our ~~Company’s~~ principal executive officer or acting in similar capacity during the last completed fiscal year, regardless of compensation level, and other individuals as required by Item 402(m)(2) of Regulation S-K. We refer to all of these individuals ~~collectively~~ collectively as our “named executive officers.”

SUMMARY COMPENSATION TABLE

	Year Ended	Salary and Fees	Bonus	Total
Name and Principal Position	July 31,	($)	($)	($)
Dr. Raouf Guirguis --Former Chairman and CEO (1)	2021	-	-	-
Nicholas P. DeVito --Chairman and CEO (1)	2022	-	-	-
Nicholas P. DeVito --Chairman and CEO (2)	2021	-	-	-
	2023	-	-	-
	2022	-	-	-

(1) ~~Resigned~~Appointed ~~from~~as ~~all~~of ~~positions with the Company on~~ April 15, 2021.

(2) Appointed as of April 15, 2021.

Outstanding Equity Awards at Fiscal Year-End

As of July 31, ~~2022~~2023, no stock, stock options, or other equity securities were awarded to our named executive officers.

Employment Agreements, Termination of Employment and Change-in-Control Arrangements with our Executive Officers

Our sole executive officer, Nicholas DeVito, does not have a compensation agreement with us.

Compensation of Directors

None of our directors was compensated for services in ~~2021~~2022 or ~~2022~~2023.

Director Agreements

General

Our directors may receive equity in the form of options at fair market value for their service on our board of directors. We do not intend to pay cash compensation to directors.

Term of Office

Each of our directors is elected to hold office for a one-year term or until his successor is elected and qualified.

2226

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The following table sets forth certain information regarding our common stock beneficially owned as of October 25 29, ~~2022~~2024, for (i) each stockholder known to be the beneficial owner of 5% or more of our outstanding voting common stock and our voting series A non-convertible ~~preferred~~ preferred stock, (ii) each executive officer and director, and (iii) all executive officers and directors as a group. In general, a person is deemed to be a beneficial owner of a security if that person has or shares the power to vote or direct the voting of such security, or the power to dispose or to direct the disposition of such security. A person is also deemed to be a beneficial owner of any securities of which the person has the right to acquire beneficial ownership within 60 days. Shares of common stock subject to options, warrants or convertible securities exercisable or convertible within 60 days are deemed outstanding for computing the percentage of the person or entity holding such options, warrants or convertible securities but are not deemed outstanding for computing the percentage of any other person. Percentages are determined based on ~~940~~419,~~621~~601 shares of common stock of the Company issued and outstanding as of October 29 ~~25, 2022~~2024. To the best of our knowledge, subject to community and marital property laws, all persons named have sole voting and investment power with respect to such shares, except as otherwise noted.

Name and Address of Beneficial Owner (1)	Common Stock		~~Series A Non-Convertible Preferred Stock~~
	Amount and Nature of Beneficial Ownership	Percent of Class Beneficially Owned (2)	~~Amount and Nature of Beneficial Ownership~~	~~Percent of Class Beneficially Owned (3)~~
Officers and Directors
Nicholas DeVito -Chief Executive Officer, Chief Financial Officer, President, Treasurer and Secretary	05,000,000	06.9%	~~1,000~~	~~100%~~
All Officers and Directors as a group (1 persons)	0	0%	1,000	100%
Dr. Raouf Guirguis – Director (3)	34,647,800	47.6%
5% Stockholders
Mr. Nathan Keele – Director	18,903,200	26.0%
Dr. Raouf Guirguis (4) 10202 Sherman Heights Place Columbia, MD 21044-5416	50,000	5.3%	-	-
All Officers and Directors as a group (1 persons)	58,551,000	80.5%
5% Stockholders
Loretta Guirguis 18 Lafayette Pl Woodmere, NY 11598	5,050,000	6.9%
Sandra J. DeLuzio (Guirguis) 4 Shoal Dr Corona Del Mar, Ca 92625	5,050,000	6.9%
Kyrollos Guirguis 7911 Westpark Dr Tysons Corner Va	5,050,000	6.9%
Arian Guirguis 18 Lafayette Pl Woodmere, NY 11598	5,050,000	6.9%

(1)

Unless otherwise indicated, the address of the named beneficial owner is c/o Point of Care Nano-Technology, Inc. 109 Ambersweet Way, Davenport, FL 33897.

(2) Based on ~~940~~72,690,621 shares of our common stock outstanding as of October 2529, ~~2022~~2024.

(3) ~~Based~~Includes ~~on 1~~5,050,000 shares of ~~series~~Common AStock ~~non-convertible~~held ~~preferred~~in ~~stock~~the ~~outstanding~~name asof Loretta Guirguis, the wife of ~~October~~Dr. 25Raouf Guirguis and 7,096,800 ~~2022~~shares of Common Stock held in the name of Point of Care Nano Technology, LLC, a private LLC managed by Dr. Guirguis.

(4) Dr. Guirguis controls 50,000 shares of our common stock indirectly via his wife’s ownership of those shares.

Item 13. Certain Relationships and Related Transactions, and Director Independence

Certain Relationships and Related Transactions

None, during the fiscal years ended July 31, ~~2021~~2022, and ~~2022~~2023.

Independent Directors

None

2327

Item 14. Principal Accounting Fees and Services

K.Fruci R.& ~~Margetson~~Associates ~~Ltd.~~II, ~~Chartered~~PLLC ~~Accountant (“K.R. Margetson”)~~ is ~~the~~our ~~Company’s~~ independent public accountant who has audited ~~the~~ our fiscal years ended July 31, ~~2021~~2022 and July 31, ~~2022~~2023. The aggregate fees billed for the two most recently completed fiscal years ended July 31, ~~2021~~ 2023 and July 31, 2022 for professional services rendered by ~~K.R.~~Fruci ~~Margetson~~ were as follows:

	2021		2022
	2022		2023
Audit Fees and Audit Related Fees	$	67,~~000~~470	$	~~7,470~~-
Tax Fees		-		0-
All Other Fees		-		0-
Total	$	67,~~000~~470	$	~~7,470~~-

Policy on Pre-Approval by the Board of Services Performed by Independent Auditors

Our board of directors pre-approves all services provided by our independent auditors. All of the above services and fees were reviewed and approved by our board of directors either before or after the respective services were rendered.

2428

PART IV

Item 15. Exhibits, Financial Statement Schedules

Exhibit		Incorporated by Reference			Filed or Furnished
Number	Exhibit Description	Form	Exhibit	Filing Date	Herewith
3.1	Articles of Incorporation,	S-1	3.1	10/25/2010
3.2	Amendment to Articles of Incorporation, dated August 28, 2014.	8-K	3.1	10/30/2014
3.3	Amendment to Articles of Incorporation, dated March 31, 2015.	8-K	3.1	04/08/2015
3.4	Certificate of Amendment by Custodian dated July 1, 2020	10-12g	3.4	10/15/2021
3.5	Certificate of Designation of the Series A Non-Convertible Preferred Stock	10-12g	3.5	10/15/2021
3.6	Bylaws.	S-1	3.2	10/25/2010
10.1	License Assignment Agreement ~~with~~by ~~Lamina~~and ~~Equities~~among ~~Corporation~~Point of Care Nano-Technology, ~~dated~~Inc., ~~February~~DRG 25Transfer, ~~2015~~Inc. and Dr. Raouf Guirguis dated as of March 23, 2022	8-K	10.12	024/2714/~~2015~~2022
10.2	~~Stipulation~~Agreement of Conveyance Transfer and ~~Order~~Assignment ~~Approving~~by ~~Yosef~~and ~~Yafe~~among toPoint beof ~~Substituted~~Care asNano-Technology, ~~Custodian~~Inc., DRG Transfer, Inc. and Dr. Raouf Guirguis dated ~~February~~as 17of March 23, ~~2020~~2022	108-~~12g~~K	10.23	104/1514/~~2021~~2022
10.3	~~Separation~~Licensing and ~~Release~~Distribution Agreement dated as of ~~Claims~~April ~~Agreement~~10, 2022 by and between Point of Care Nano-Technology, Inc. and ~~Dr.~~Cedoga ~~Raouf~~Consulting ~~Guirguis dated April 15, 2021~~LLC	108-~~12g~~K	10.34	104/1514/~~2021~~2022
10.4	~~Separation~~Exclusive Representative and ~~Release~~License ~~of Claims~~ Agreement ~~by and~~ between ~~Point~~Duo ofSciences ~~Care Nano-Technology,~~ Inc. and ~~Ayman~~Lucy ~~El-Salhy~~Pet ~~dated~~Products ~~April 15, 2021~~Inc.	10-~~12g~~Q	10.41	106/1514/~~2021~~2022
10.5	~~Assignment~~Asset ~~and~~Purchase ~~Assumption~~ Agreement dated May 20, 2024 by and between Point of Care Nano-Technology, Inc. and ~~Dr.~~Point ~~Raouf~~of ~~Guirguis~~Care ~~dated April 15~~Nano-Technology, ~~2021~~LLC	108-~~12g~~K	10.51	105/1520/~~2021~~24
10.6	~~Settlement~~License Agreement dated May 920, ~~2021~~2024 bybetween ~~and among Yosef Yafe, Ayman El Salhya and~~ Point of Care Nano-Technology, Inc. and Zeus Diagnostics, LLC	108-~~12g~~K	10.62	105/1520/~~2021~~24
10.7	Voluntary Dismissal of the Application for Appointment of Custodian, dated May 14, 2021	10-12g	10.7	10/15/2021
10.8	License Assignment Agreement by and among Point of Care Nano-Technology, Inc., DRG Transfer, Inc. and Dr. Raouf Guirguis dated as of March 23, 2022	8-K	10.2	4/14/2022
10.9	Agreement of Conveyance Transfer and Assignment by and among Point of Care Nano-Technology, Inc., DRG Transfer, Inc. and Dr. Raouf Guirguis dated as of March 23, 2022	8-K	10.3	4/14/2022
10.10	Licensing and Distribution Agreement dated as of April 10, 2022 by and between Point of Care Nano-Technology, Inc. and Cedoga Consulting LLC	8-K	10.4	4/14/2022
10.11	Exclusive Representative and License Agreement between Duo Sciences Inc. and Lucy Pet Products Inc.	10-Q	10.1	6/14/2022
31.1/31.2	Certifications of Principal Executive Officer and Principal Financial and Accounting Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002				X
32.1/32.2	Certification of Principal Executive Officer and Principal Financial and Accounting Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002				X
101.INS	Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.				X
101.SCH	Inline XBRL Taxonomy Extension Schema Document				X
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document				X
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document				X
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document				X
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document				X
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)				X

2529

SIGNATURES

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

Point of Care Nano-Technology, Inc. By: /s/ Nicholas DeVito Nicholas DeVito Chief Executive Officer and Director (Principal Executive Officer) (Principal Financial and Accounting Officer) Date: October 25, 2022

Financial Pages Contents

AUDITED FINANCIAL STATEMENTS JULY 30, 2021 AND 2020
AUDITED FINANCIAL STATEMENTS JULY 31, 2023 AND 2022
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM	F-1
CONSOLIDATED BALANCE SHEETS	F-2
CONSOLIDATED STATEMENTS OF OPERATIONS	F-3
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY	F-4
CONSOLIDATED STATEMENTS OF DEFICIT	F-4
CONSOLIDATED STATEMENTS OF CASH FLOWS	F-5
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS	F-6

K. R. MARGETSON LTD.	Chartered Professional Accountant
331 East 5th Street	Tel: 604.220.7704
North Vancouver BC V7L 1M1	Fax: 1.855.603.3228
Canada

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders of ~~Point~~ Point of Care Nano-Technology, Inc.:

Opinion on the ~~financial~~Financial ~~statements~~Statements

IWe have audited the accompanying consolidated balance sheets of Point of Care Nano-Technology, Inc. (“the Company”) as of July 31, ~~2022~~2023 and ~~2021~~2022, and the related consolidated statements of operations, ~~stockholders’~~ statement of deficit, and cash flows for each of the ~~two~~ years ~~then~~in the two-year period ended July 31, 2023, and the related notes (collectively referred to as the “ financial statements’). In myour opinion, the ~~consolidated~~ financial statements present fairly, in all material respects, the ~~consolidated~~ financial position of the Company as atof July 31, ~~2022~~2023 and ~~2021~~2022, and the ~~consolidated~~ results of its operations and its cash flows for each of the ~~two~~ years in the two-year period ended July 31, ~~2022~~2023, in conformity with accounting principles generally accepted in ~~the~~ the United States of America.

~~Substantial Doubt about the Company’s Ability to Continue as a~~ Going Concern

The accompanying financial statements have been prepared ~~using accounting principles generally accepted in the United States of America~~ assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company ~~has~~had not ~~incurred~~yet ~~operating~~ achieved profitable operations and had accumulated losses. ~~since~~The ~~inception,~~Company ~~which~~will ~~raises~~need to raise additional cash in order to fund ongoing operations. These factors raise substantial doubt about ~~its~~the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for ~~opinion~~Opinion

These financial statements are the responsibility of the Company’s management. MyOur responsibility is to express an opinion on ~~these~~the Company’s financial statements based on my our audits. MyWe ~~company~~are is a public accounting firm registered with the Public Company Accounting Oversight Board (“United States) (PCAOB”) and is are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the ~~SEC~~Securities and Exchange Commission and the PCAOB.

I We conducted myour audits in accordance with the standards of the PCAOB. Those standards require that Iwe plan and perform anthe audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor ~~was~~were Iwe engaged to perform, an audit of its internal control over financial reporting. As part of myour audits I, amwe are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, Iwe express no such opinion.

My Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our My audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall ~~financial~~presentation ~~statement~~of ~~presentation~~the financial statements. IWe believe that myour audits provide a reasonable basis for myour opinion.

Critical Audit Matters

~~The critical~~Critical audit matters ~~communicated below~~ are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: ( 1) relate to accounts or disclosures that are material to the financial statements and (2) ~~involve~~involved our especially challenging, subjective, or complex ~~judgements~~judgments. ~~The~~We ~~communication~~determined ofthat ~~critical~~there ~~audit~~were ~~matters~~no ~~does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and I am not, by communicating the~~ critical ~~audit~~ ~~matters below, providing separate opinions on the critical~~ audit matters ~~or on the accounts or disclosures to which they relate~~.

~~As described~~Fruci in& ~~Note~~Associates ~~7 of the financial statements~~II, ~~the~~PLLC ~~license~~– ~~was~~PCAOB ~~obtained~~ID by#05525 anWe ~~obligation~~have toserved ~~issue~~as ~~300,000 common shares. The determination of~~ the ~~fair~~Company’s ~~value~~auditor ofsince ~~the~~2024. ~~transaction~~Spokane, ~~included~~Washington ~~various~~October ~~factors.~~29, 2024

I identified the determination of fair value as a critical audit matter. The Company’s determination was subjective. Specifically, there was a high degree of subjective auditor judgment in evaluating how the Company determined (1) whether the value of the shares given up or the asset received was more easily determined, (2) what the estimated cash flows from the license would be, (3) how long would the asset produce positive cash flows, and (4) what would be a reasonable discount rate to reflect the uncertainty of the projections.

Addressing the matter involved performing procedures and evaluation audit evidence in connection forming my overall opinion on the financial statements. These procedures include the following among others: (1) Examining the market value and volume of sales of the Company’s shares; (2) reviewing market analysis for the Company’s industry, (3) analyzing the Company’s current results, (3) preparing my own analysis by using experience gained in retroactive review of discounting cash flows from similar situations.

/s/ K. R. Margetson Ltd

Chartered Professional Accountant

I have served as the Company’s auditor since 2021

Vancouver, Canada

October 24, 2022

PCAOB ID: 1212

F-1

POINT OF CARE NANO-TECHNOLOGY, INC. CONSOLIDATED BALANCE SHEETS AsFor ofthe Year Ended July 31, ~~2022~~2023 and July 31, ~~2021~~2022

	July 31			July 31
	July 31, 2023			July 31, 2022 Restated (Note 1)
	2022			2021
ASSETS
Current Assets
Cash	$	~~3,198~~498		$	-3,198
Prepaid expense		2,917			-
Prepaid Expenses		5,280			2,917
Current Assets		65,~~115~~778			-6,115
Intangible asset – license (Note 7)		123,466			-
Intangible Asset - License (Note 7)		118,865			123,466
Total Assets	$	~~129~~124,~~581~~643		$	-129,581
LIABILITIES AND SHAREHOLDERS’ DEFICIT
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current Liabilities
Accounts payable and accrued charges	$	213,335		$	20,240
Accounts Payable and Accrued Expenses	$	141,414		$	88,335
Total Liabilities	$	~~213~~141,~~335~~414		$	2088,~~240~~335
Commitments and Contingencies		-			-
Stockholders’ Deficit
Preferred stock, par value $0.0001,(Note 5) 10,000,000 shares authorized; 1,000 shares issued and outstanding		1			-
Preferred Stock, par value $0.0001, (Note 5)10,000,000 shares authorized;1,000 shares issued and outstanding		1			1
Common stock, par value $0.0001, (Note 5) 100,000,000 shares authorized 940,621 shares issued and outstanding		940			940
Common Stock, par value $0.0001, (Note 5)100,000,000 shares authorized;420,621 shares issued and outstanding (940,621 in 2022)		42			94
520,000 Treasury shares		(520	)		-
Unissued Common Stock		750,000			750,000
Additional paid-in capital		120,191,707			120,191,187
Share Subscriptions Received (Note 5)		20,000			-
Accumulated deficit		(120,275,882	)		(120,212,367	)
Treasury Stock - 520,000 shares		-			(52	)
Total Stockholders’ Deficit		(83,754	)		(20,240	)
Additional Paid-In Capital		120,192,085			120,192,085
Total Liabilities and Stockholders’ Deficit	$	129,581		$	-
Accumulated Deficit		(120,978,899	)		(120,900,882	)
Total Stockholders’ Deficit		(16,771	)		41,246
Total Liabilities and Stockholders’ Deficit	$	124,643		$	129,581

See accompanying notes to the ~~interim~~ financial statements.

F-2

POINT OF CARE NANO-TECHNOLOGY, INC. CONSOLIDATED ~~STATEMENTS~~STATEMENT OF OPERATIONS For the ~~Years~~Year Ended July 31, ~~2022~~2023 and ~~2021~~July 31, 2022

	For the Year Ended July 31
	For the Twelve			For the Twelve
	2022			2021
	Months Ended			Months Ended
Royalty revenue	$	100,000		$	-
	July 31, 2023			July 31, 2022
Royalty fee		90,000			-
				Restated (Note 1)
Net royalty income		10,000			-
Operating Expenses:
Operating expenses
Professional Fees	$	56,548		$	51,800
Professional fees		51,800			7,500
Amortization Expense		4,601			1,534
General and administration		20,180			-
General and Administrative Expense		16,868			20,180
Amortization		1,534			-
Officer Compensation		-			1
Officer compensation		1			-
Total Expenses:	$	78,017		$	73,515
Operating expenses		73,515			7,500
Net Operating and Comprehensive Loss	$	(78,017	)	$	(73,515	)
Net loss and comprehensive loss	$	(63,515	)	$	(7,500	)
Other Income:
Weighted average Net Loss per share, basic and diluted	($	0.08	)	$	0.00
Royalty Income		-			100,000
Weighted average number of common shares outstanding		787,183			940,621
Total Other Income	$	-		$	100,000
Other Expenses:
Impairment Expense		-			625,000
Royalty Fee		-			90,000
Total Other Expense	$	-		$	715,000
Net Other Expense:	$	-		$	(615,000	)
Net and Comprehensive Loss	$	(78,017	)	$	(688,515	)
Weighted average Net Loss per share, basic and diluted	$	(0.10	)	$	(0.87	)
Weighted average number of common shares outstanding		751,142			787,183

See accompanying notes to the ~~interim~~ financial statements.

F-3

POINT OF CARE NANO-TECHNOLOGY, INC. CONSOLIDATED STATEMENTS OF DEFICIT For the Year Ended July 31, 2023 and July 31, 2022 (Restated, Note 1)

	Preferred Stock					Common Stock						Treasury Stock						Additional Paid-in Capital			Accumulated Deficit			Total Stockholders’ Deficit
																														Total
	#					#						#
												Share Subscription			Unissued									Additional			Accumulated			Stockholders’
Balance, July 31, 2021		-	$	-			940,621		$	940			-		$	-		$	120,191,187		$	(120,212,367	)	$	(20,240	)
	Preferred Stock					Common Stock						Received			Common Stock			Treasury Stock						Paid-In Capital			Deficit			Deficit
Shares issued		1,000		1			-			-			-			-			-			-			1
			$						$			$			$						$			$			$			$
Net loss for the period		-		-			-			-			-			-			-			(42,255	)		(42,255	)
Balance, July 31, 2022		1,000		1			940,621			94			-			750,000			(520,000	)		(52	)		120,192,085			(120,900,882	)		41,246
Balance, October 31, 2021		1,000		1			940,621			940			-			-			120,191,187			(120,254,622	)		(62,494	)
Share Subscription Received		-		-			-			-			10,000			-			-			-			-			-			10,000
Net loss for the period		-		-			-			-			-			-			-			(13,795	)		(13,795	)
Net Loss for the period		-		-			-			-			-			-			-			-			-			(28,071	)		(28,071	)
Balance, January 31, 2022		1,000		1			940,621			940			-			-			120,191,187			(120,268,417	)		(76,289	)
Balance, October 31, 2022		1,000		1			940,621			94			10,000			750,000			(520,000	)		(52	)		120,192,085			(120,928,953	)		23,175
Settlement (Note 6)		-		-									(520,000	)		(520	)		520			-			-
Share Subscription Received		-		-			-			-			10,000			-			-			-			-			-			10,000
Net loss for the period		-		-			-			-			-			-			-			(5,837	)		(5,837	)
Net Loss for the period		-		-			-			-			-			-			-			-			-			(13,154	)		(13,154	)
Balance, April 30, 2022		1,000		1			940,621			940			(520,000	)		(520	)		120,191,707			(120,274,254	)		(82,126	)
Balance, January 31, 2023		1,000		1			940,621			94			20,000			750,000			(520,000	)		(52	)		120,192,085			(120,942,107	)		20,021
Net loss for the period		-		-			-			-			-			-			-			(1,628	)		(1,628	)
Share Cancellation		-		-			(520,000	)		(52	)		-			-			520,000			52			-			-			-
Balance, July 31, 2022		1,000	$	1			940,621		$	940			(520,000	)	$	(520	)	$	120,191,707		$	(120,275,882	)	$	(83,754	)
Net Loss for the period		-		-			-			-			-			-			-			-			-			(9,773	)		(9,773	)
Balance, April 30, 2023		1,000		1			420,621			42			20,000			750,000			-			-			120,192,085			(120,951,880	)		10,248
Net Loss for the period		-		-			-			-			-			-			-			-			-			(27,019	)		(27,019	)
Balance, July 31, 2023		1,000		1			420,621			42			20,000			750,000			-			-			120,192,085			(120,978,899	)		(16,771	)
																														Total
												Share Subscription			Unissued									Additional			Accumulated			Stockholders’
	Preferred Stock					Common Stock						Received			Common Stock			Treasury Stock						Paid-In Capital			Deficit			Deficit
			$						$			$			$						$			$			$			$
Balance, July 31, 2021		-			-		940,621			94			-			-			-			-			120,187,430			(120,212,367	)		(24,843	)
Shares Issued		1,000		1			-			-			-			-			-			-			-			-			1
Net Loss for the period		-		-			-			-			-			-			-			-			-			(42,255	)		(42,255	)
Balance, October 31, 2021		1,000		1			940,621			94			-			-			-			-			120,187,430			(120,254,622	)		(67,097	)
Net Loss for the period		-		-			-			-			-			-			-			-			-			(13,795	)		(13,795	)
Balance, January 31, 2022		1,000		1			940,621			94			-			-			-			-			120,187,430			(120,268,417	)		(80,892	)
Net Loss for the period		-		-			-			-			-			-			-			-			-			(5,837	)		(5,837	)
Balance, April 30, 2022		1,000		1			940,621			94			-			-			-			-			120,187,430			(120,274,254	)		(86,729	)
Settlement (Note 6)		-		-			-			-			-			-			(520,000	)		(52	)		4,655			-			4,603
Unissued Common Stock		-		-			-			-			-			750,000			-			-			-			-			750,000
Net Loss		-		-			-			-			-			-			-			-			-			(626,628	)		(626,628	)
Balance, July 31, 2022		1,000		1			940,621			94			-			750,000			(520,000	)		(52	)		120,192,085			(120,900,882	)		41,246

~~For~~See ~~the~~accompanying ~~Year~~notes ~~Ended~~to ~~July~~the financial ~~31, 2021~~statements.

	Common Stock				Additional Paid-in Capital		Accumulated Deficit			Total Stockholders’ Deficit
	#
Balance, July 31, 2020		940,621	$	940	$	120,191,187	$	(120,204,867	)	$	(12,740	)
Net loss for the period		-		-		-		-			-
Balance, October 31, 2020		940,621		940		120,191,187		(120,204,867			(12,740	)
Net loss for the period		-		-		-		-			-
Balance, January 31, 2021		940,621		940		120,191,187		(120,204,867			(12,740	)
Net loss for the period		-		-		-		-			-
Balance, April 30, 2021		940,621		940		120,191,187		(120,204,867	)		(12,740	)
Net loss for the period		-		-		-		(7,500	)		(7,500	)
Balance, July 31, 2021		940,621	$	940	$	120,191,187	$	(120,212,367	)	$	(20,240	)

See accompanying notes to the interim financial statements.

F-4

POINT OF CARE NANO-TECHNOLOGY, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS For the Year Ended July 31, ~~2022~~2023 and July 31, ~~2021~~2022

	For the Year Ended July
	For the Twelve			For the Twelve
	2022			2021
	Months Ended			Months Ended
Cash flows from operating activities
	July 31,2023			July 31, 2022
Net loss for the year	$	(63,515	)	$	(7,500	)
				Restated (Note 1)
Non-cash expense
Cash Flows from Operating Activities:
Amortization		1,534			-
Net Loss	$	(78,017	)	$	(688,515	)
Officer compensation		1			-
Non Cash Expense:
Change in working capital items
Amortization		4,601			1,534
Prepaid expense		(2,917	)		-
Impairment of License		-			625,000
Accounts payable		68,095			7,500
Officer Compensation		-			1
Net cash flows from operating activities		3,198			-
Change in Working Capital Items:
Change in cash for the year		3,198			-
Accounts payable and Accrued expenses		53,079			68,095
Cash, beginning of year		-			-
Prepaid expense		(2,363	)		(2,917	)
Cash, end of year	$	3,198		$	-
Net Cash Provided (Used) by Operating Activities	$	(22,700	)	$	3,198
Supplemental disclosures of cash flow Information Cash paid during the year for:
Cash Flows from Financing Activities:
Share Subscriptions Received		20,000			-
Net Cash Provided by Financing Activities	$	20,000		$	-
Change in cash for the period		(2,700	)		3,198
Beginning Cash		3,198			-
Ending Cash	$	498		$	3,198
Supplemental disclosures of cash flow - cash paid for :
Interest	$	-		$	-
Income tax	$	-		$	-
Income Tax	$	-		$	-
License fee to be paid in common shares (unpaid)	$	125,000		$	-
Unpaid license fees to be paid in common shares	$	-		$	750,000.00

See accompanying notes to the ~~interim~~ financial statements.

F-5

POINT OF CARE NANO-TECHNOLOGY, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS JULY 31, ~~2022~~2023 AND ~~2021~~2022

Note 1

COMPANY AND BACKGROUND

Point of Care Nano-Technology, Inc. (the “Company”) was incorporated under the laws of the State of Nevada on June 10, 2010, under the name of “Alternative Energy and Environmental Solutions, Inc.” On August 28, 2014, the Company filed an amendment to its Articles of Incorporation changing the name of the Company to “Unique Growing Solutions, Inc.” On March 31, 2015, the Company filed an amendment to its Articles of Incorporation changing the name of the Company to “Point of Care Nano-Technology, Inc.”

On February 26, 2015, ~~the~~our ~~Company’s~~ business model was related to using its license, under a certain license agreement (the “License Agreement”) from Lamina Equities Corporation, to first develop and then manufacture saliva-based medical diagnosis products. The Company was not successful and discontinued the majority of its operations by July 31, 2016. Beginning from August 2016, ~~the~~our ~~Company’s~~ plan, which it has since discontinued, was to provide business services and financing to emerging growth entities.

On April 15, 2021, the Company accepted the resignations of Dr. Guirguis and Mr. El-Salhy, received a mutual release from both, and appointed Mr. Nicholas DeVito to be Director, Chief Executive Officer and Chief Financial Officer. In addition, for his services to the Company, Mr. DeVito was awarded 1,000 shares of Class A Preferred Stock that grants him 80% voting rights.

Also on April 15, 2021 the Company agreed to form a subsidiary and transfer all debts and the License Agreement back to Dr. Guirguis in exchange for 520,000 shares of Common Stock. On August 231, 2021, the Company formed the wholly owned subsidiary, DRG Transfer, Inc. This transaction closed on March 26, 2022.

On July 2, 2021, the Company incorporated a wholly owned subsidiary, Duo Sciences, Inc. (“DSI”).

On April 11, 2022, the Company, through DSI, acquired an exclusive license to distribute certain intellectual property in animal nutrition and animal supplements from Cedoga Consulting, LLC (“Cedoga”). On April 19, 2022, DSI signed an exclusive sales and promotion agreement with Lucy Pet Products Inc. (“Lucy”) pursuant to which Lucy will manufacture, market and distribute pet products from the Cedoga intellectual property.

U.S. patent application 16/930,604 was allowed on March 29, 2023, and will issue shortly, further strengthening our subsidiary, DSI, intellectual property position and coverage for its DUOS products. The allowed claims are directed to an edible pet chew that contains a thermo-processed shell having a cylindrical shape and that includes cellulosic fibers, a humectant, and a gelling agent, and within the shell is a cold-formed filler that contains a fat mimicking composition and a thermally labile active containing an enzyme. The pet chew provides oral care properties and contains thermal labile nutrients and/or actives whose nutrient values and activities are preserved. The pet chews provide salivatory stimulation when consumed by the pet, which in combination with the other ingredients of the pet chew provide dental care properties to remove dental plaque, stain, and tartar on a tooth surface, as well as protection of the oral and perioral tissues. A continuation patent application seeking to further protect the pet chew oral care technology was also filed. The application has been assigned serial number 18/133,381 and the filing date was April 11, 2023.

F-6

The Company’s July 31, 2022 financial statements have been restated to reflect changes to the valuation of the original Lucy Pet Products license. This original value is now based on the market prices of the shares at the time of the transaction and was impaired at year end 2022. In addition, corrections to the par value of our common stock are now reflected in the financial statements. See the Table below for the adjustments.

Account	As Originally Filed	As Restated		Variance			Explanation
License	125,000.00		125,000.00		-		Original purchase of license value was increased by $750,000; restatement includes write off of ($125,000) license fee payable and subsequent ($625,000) impairment
License Fee Payable	125,000.00		-		125,000.00		Original purchase of license value was increased by $750,000; restatement includes write off of ($125,000) license fee payable and subsequent ($625,000) impairment
License Impairment	-		625,000.00		(625,000.00	)	Original purchase of license value was increased by $750,000; restatement includes write off of ($125,000) license fee payable and subsequent ($625,000) impairment
Royalty Revenue	100,000.00		100,000.00		-		Reclassification from Operating Income to Other Income
Royalty Fees	90,000.00		90,000.00		-		Reclassification from Operating Expense to Other Expense
Common Stock to be issued	-		750,000.00		(750,000.00	)	Common Stock due to be issued for increase in original purchase value of license of $750,000
Common Stock	940.00		94.00		846.00		Original par value was incorrect at .001/share; corrected at .0001/share
Treasury Stock	520.00		52.00		468.00		Original par value was incorrect at .001/share; corrected at .0001/share

The Company’s principal executive office location and mailing address is 109 Ambersweet Way, Davenport, FL 33897.

Note 2

CONTROL BY PRINCIPAL OWNERS

The directors and executive officers own, directly or indirectly, beneficially and in the aggregate, the majority of the voting power of the outstanding capital stock of the Company. Accordingly, directors, executive officers and their affiliates, if they voted their shares uniformly, would have the ability to control the approval of most corporate actions, including approving significant expenses, increasing the authorized capital and the dissolution, merger, or sale of ~~the~~our ~~Company’s~~ assets.

Note 3

GOING CONCERN

These financial statements have been prepared in accordance with generally accepted principles applicable to a going concern, which assumes that the Company will be able to meet its obligations and continue its operations for its next twelve months. Realization values may be substantially different from carrying values as shown and these financial statements do not give effect to adjustments that would be necessary to the carrying values and classifications of assets and liabilities should the Company be unable to continue as a going concern.

At July 31, 2022, the Company had not yet achieved profitable operations and had accumulated losses of $120,275,882 and had $3,198 cash on hand. The Company will need to raise additional cash in order to fund ongoing operations over the next 12 month period. These factors which casts substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to generate future profitable operations and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. No adjustments to the consolidated financial statements have been made as a result of this concern.F-7

~~F-6~~At July 31, 2023, the Company had not yet achieved profitable operations and had accumulated losses of $120,978,899 and had $498 cash on hand. The Company will need to raise additional cash in order to fund ongoing operations over the next 12 month period. These factors which casts substantial doubt about our ability to continue as a going concern. Our ability to continue as a going concern is dependent upon its ability to generate future profitable operations and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. No adjustments to the consolidated financial statements have been made as a result of this concern.

Note 4

ACCOUNTING POLICIES

The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America, the more significant of which are as follows:

Consolidation

The accompanying consolidated financial statement include the accounts of the Company and its wholly owned subsidiary Duo Sciences Inc. (“DSI”)

Use of Estimates

Financial Instruments

Fair Value Measurements

F-8

~~F-7~~Revenue Recognition

Income Taxes

Comprehensive Income (Loss)

Net Income (Loss) per Common Share

F-9

Segment Reporting

Intangible assets

Intangible asset are non-monetary identifiable assets, controlled by the Company that will produce future economic benefits, based on reasonable and supportable assumptions about conditions that will exist over the life of the asset. An intangible asset that does not meet these attributes will be recognized as an expense when it is incurred. Intangible assets that do, are capitalized and initially measure at cost. Those with a determinable life will be amortized on a systematic basis over their future economic life. Those with an indefinite useful life shall not be amortized until its useful life is determined to be longer than indefinite. An intangible asset subject to amortization shall be periodically reviewed for impairment. A recoverability test will be performed and, if applicable, unscheduled amortization is considered.

Non-cash transactions

F-8

Related Parties

The Company adopted FASB ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

Recent Accounting Pronouncements

Note 5

COMMON and PREFERRED STOCK

The Company has authorized capital of 100,000,000 shares of common stock, par value of $0.0001 per share, and 10,000,000 shares of “blank check” preferred stock, par value of $0.0001 per share, of which ~~1,000~~none ~~shares~~ have been designated as Series A Nonconvertible Preferred Stock (the “Series A Preferred Stock”). During the year ended July 31, ~~2022~~2023, the Company had the following transactions:

On June 8, 2022, the Company received approval from the Financial Industry Regulatory Authority to effect a 50:1 reverse split of ~~the~~our ~~Company’s~~ outstanding common stock. The split was reflected in the public markets on June 9, 2022 and has been given retroactive disclosure in the financial statements. Accordingly, all references to common shares in these financial statements reflect the reverse split.

On August 2, 2021, the Company issued 1,000 Series A Preferred Stock to Nicholas DeVito, the Company’s Chief Executive Officer as compensation. The Preferred Stock gives DeVito 80% control of the voting stock of the Company.F-10

On ~~April~~August 102, ~~2022~~2021, the Company ~~entered~~issued ~~into~~1,000 anSeries ~~agreement~~A ~~under~~Preferred ~~which~~Stock ~~it agreed~~ to ~~issue~~Nicholas ~~300~~DeVito,~~000~~ ~~common~~our ~~shares~~Chief inExecutive ~~order~~Officer toas ~~obtain~~compensation. ~~a license~~The toPreferred ~~distribute~~Stock ~~product~~gives ~~(See~~DeVito ~~below).~~80% ~~The~~control ~~Company~~of ~~has~~the ~~not~~voting ~~yet~~stock ~~issued~~of ~~those~~the ~~shares~~Company. ~~and~~Mr. ~~the~~DeVito ~~obligation~~surrendered tohis dopreferred soshares isin ~~included~~exchange for in5,000,000 ~~the~~shares ~~accounts as~~of aCompany ~~$125~~common stock on May 21,~~000~~ ~~liability~~2024.

On April 10, 2022, the Company entered into an agreement under which it agreed to issue 300,000 common shares in order to obtain a license to distribute product (See below). The Company has not yet issued those shares and the obligation to do so is recorded as a $750,000 unissued stock in equity.

On April 15, 2022, as part of the Settlement agreement (See below), the Company received into treasury 520,000 shares of common stock (26,000,000 pre reverse split shares).

~~There~~On ~~were~~June no8, ~~transactions~~2022, in the Company’s ~~common~~received orapproval ~~preferred~~from the Financial Industry Regulatory Authority to effect a 50:1 reverse split of our outstanding common stock. The split was reflected in the ~~year~~public ~~ended~~markets ~~July~~on 31June 9, ~~2021~~2022 and has been given retroactive disclosure in the financial statements. Accordingly, all references to common shares in these financial statements reflect the reverse split.

~~There~~On ~~were~~August no24, ~~warrants~~2022, orthe ~~options~~Company ~~outstanding~~completed asa financing with an investor for $20,000 in exchange for Units consisting of ~~July~~(i) 31one share of common stock, ~~2022~~par value $0.0001 per share for $0.10 per share, (ii) one LOI option to purchase one share of common stock for $0.20 per share upon the Company signing a letter of intent with a third party and (iii) one Agreement option to purchase one share of common stock for $0.30 per share upon the Company signing an agreement with a third party.

There were no warrants or options outstanding as of July 31, 2023.

Note 6

SETTLEMENT AGREEMENT

On April 15, 2021, the Company formed a wholly owned subsidiary, DRG Transfer Inc. (“DRG”) and transferred all Company debts ~~relating~~ relating to the License Agreement business and the License Agreement to DRG to be split off to Dr. Guirguis in exchange for 520,000 ~~share~~ shares (26,000,000 shares pre reverse split) of ~~the~~our ~~Company’s~~ common stock held by Dr. Guirguis. This transaction closed on March 26, 2022 with Dr. Guirguis giving up and transferring to DRG all the rights, title and interest in the 520,000 shares and DRG contributing all of the legacy business debt and the License Agreement to DRG Transfer, Inc, a Nevada corporation, and transferring all of the outstanding capital stock in DRG Transfer, Inc. to Dr. Guirguis Outstanding debts of the Company that were generated while Mr. Guirguis operated the Company, measured as of April 15, 2021, consisted solely of unknown contingent liabilities (which could be identified or quantified at that time and which, to date, have been non-material or nil.

Note 7

LICENSE PURCHASED and INTANGIBLE ASSETS

On April 11, 2022, the Company, through its wholly owned subsidiary DSI, acquired an exclusive license to distribute in the USA, Canada and Mexico, certain intellectual property in animal nutrition and animal supplements from Cedoga Consulting, LLC. The Company receives 10% of all licensing fees due to Cedoga in exchange for 300,000 post reverse split shares of common stock of the Company. Under the terms of the agreement, the Company will pay royalties from sub-licensing on the following basis:

●

90% of net royalties for sale and initial payments up to $100,000,000 per calendar year.

F-9

●

95% of net royalties received for continuing sales above $100,000,000 per calendar year.

●

90% of any lump up-front payment sub-licensing fees.

● Option to purchase 200,000 shares of ~~the~~our ~~Company’s~~ common stock when net sales exceed $100,000,000.

The license value has been based on the expected discounted cash flows the license will generate to the Company over its estimated 10 year life. The Company’s common shares are very lightly traded and management determined that their market value are not reliable as a determinant of value for this transaction.F-11

The license value has been based on the value of the common shares at the time of the transaction and originally valued at $750,000. After further financial projection analysis we recorded an impairment of $625,000 reducing the total value of the license to $125,000.

Schedule of License Purchased

	As of July 31
	2022		2021
	2023		2022
License	$	125,000	$	-125,000
Accumulated amortization		16,~~534~~135		-1,534
Balance, end of year	$	~~123~~118,~~466~~865	$	-123,466

Note 8

EXCLUSIVE SALES SUB-LICENSING AGREEMENT

On April 19, 2022, DSI signed an exclusive sales and promotion sub-licensing agreement with Lucy Pet Products Inc. (“Lucy”) pursuant to which Lucy will manufacture, market and distribute pet products derived from the Cedoga intellectual property. The terms of the sub-licensing agreement are as follows:

	●	Lucy will pay the Company a one-time sub-license fee of $100,000 on execution of the sub-licensing agreement.
	●	Lucy will pay the Company royalties of 5% of Net Revenue, calculated and payable quarterly. Net Revenue is defined as total revenue less direct cost of materials, manufacturing, packaging and delivery expenses and less excise, sales or similar taxes.

●

Lucy will pay the Company a one-time sub-license fee of $100,000 on execution of the sub-licensing agreement.

●

Lucy will pay the Company royalties of 5% of Net Revenue, calculated and payable quarterly. Net Revenue is defined as total revenue less direct cost of materials, manufacturing, packaging and delivery expenses and less excise, sales or similar taxes.

On May 11, 2022, the Company received the first payment from Lucy of $100,000 under its sub-license agreement with Lucy and remitted $90,000 to Cedoga according to the Cedoga license agreement.

Note 9

INCOME TAXES

As at July 31, ~~2022~~2023, no tax benefit has been recorded with respect to the net operating loss in the financial statements as the management of the Company believes that the realization of ~~the~~our ~~Company’s~~ net deferred tax assets would not be considered more likely than not and accordingly, the potential tax benefits of the net loss carry-forwards are offset by the full valuation allowance. The Company has a net operating loss carryforward of approximately $1,813,968.

Income tax recovery differs from that which would be expected from applying the effective tax rates to the net loss for the years ended July 31, ~~2022~~2023 and ~~2021~~2022 as follows:

Schedule of Income tax Reconciliation

	Year Ended July 31
	2022			2021
	2023			2022
Net loss for the year	$	(6378,~~515~~017	)	$	(7688,~~500~~515	)
Statutory and effective tax rate		25.46	%		25.46	%
Expected income tax recovery	$	(1619,~~162~~863	)	$	(1688,~~909~~515	)
Tax benefit deferred		1619,~~162~~863			1175,~~909~~295
Income taxes recorded	$	-		$	-

F-12

Schedule of Deferred Tax Assets

	Year Ended July 31
	2022			2021
	2023			2022
Tax losses carried forward	$	1,814,000		$	1,~~750~~814,000
Statutory and effective tax rate		25.46	%		25.46	%
Deferred tax asset	$	462,000		$	~~446~~462,000
Valuation allowance		(462,000	)		(~~446~~462,000	)
Net deferred tax asset	$	-		$	-

F-Our income tax filings are subject to audit by various taxing authorities. Our open audit periods include from Inception (June 10, 2010) to the current tax year.

The Company’s income tax filings are subject to audit by various taxing authorities. The Company’s open audit periods include from Inception (June 10, 2010) to the current tax year.

Note 10

SUBSEQUENT EVENTS

On ~~August~~May 2420, ~~2022~~2024, ~~the~~Point ~~Company~~of ~~completed~~Care aNano-Technology, ~~financing~~Inc. ~~with~~(the an“Company”) ~~investor~~entered ~~for~~into ~~$10,000~~an inasset ~~exchange~~purchase ~~for~~agreement ~~Units consisting of~~ (ithe “Agreement”) with ~~one~~Point ~~share~~ of ~~common~~ ~~stock~~Care Nano-Technology, ~~par~~LLC ~~value~~(“Point”) ~~$0.001~~pursuant ~~per~~to ~~share~~which ~~for~~it ~~$0.10~~agreed ~~per~~to ~~share,~~acquire (iithe “Acquisition”) ~~one~~substantially all ~~LOI~~of ~~option~~the toassets ~~purchase~~of ~~one~~Point ~~share~~(the of“Assets”), ~~common~~consisting ~~stock~~primarily ~~for~~of ~~$0.20~~proprietary ~~per share~~information ~~upon~~and ~~the~~know-how ~~Company~~for ~~signing~~the adeveloping and ~~letter~~commercialization of ~~intent~~kits ~~with~~to adiagnose ~~third~~illnesses ~~party~~through ~~and~~the ~~(iii)~~testing ~~one~~of ~~Agreement~~human ~~option~~saliva, referred to ~~purchase~~as ~~one~~the ~~share~~“EZ ofSaliva” ~~common stock~~test ~~for~~kits, ~~$0.30~~and ~~per~~cash ~~share~~in ~~upon~~ the ~~Company~~amount ~~signing~~of ~~an agreement with a third party~~$101,400.

~~F-11~~In exchange for the Assets, the Company issued to Point and/or its designees 66,000,000 restricted shares of common stock (the “Consideration Shares”).

Upon the closing of the Acquisition, which effected a change of control of the Company, Dr. Raouf Guirguis, the controlling member of Point, became a director of the Company and Chief Scientific Officer. Dr. Guirguis also acquired, directly and indirectly, 34,647,800 of the Consideration Shares, or approximately 47.6% of the shares of common stock outstanding after completion of the Acquisition. Mr. Nathan Keele, an associate of Dr. Guirguis and responsible for marketing efforts at Point, also was appointed to the board of directors of the Company. Mr. Keele will continue his marketing efforts at the Company. Mr. Keele acquired 18,903,200 of the Consideration Shares, or approximately 26.5% of the shares of common stock outstanding after completion of the Acquisition.

Nicholas DeVito, the controlling stockholder of the Company prior to the Acquisition through the 1,000 shares of super-majority class A preferred stock (the “Preferred Stock”) of the Company that he held and through which he exercised eighty percent (80%) voting control over the Company, surrendered to the Company for cancellation the Preferred Stock and received, in exchange, 5,000,000 shares of common stock. Mr. DeVito will retain his positions as Chief Executive Officer, Chief Financial Officer, Treasurer and Secretary of the Company as well as his status as a member of board of directors.

F-13

In connection with the Acquisition, the Company entered into a license agreement (the “License Agreement”) with Zeus Diagnostics, LLC (“Zeus”), a Delaware limited liability company controlled by Dr. Guirguis, pursuant to which the Company acquired an exclusive, in perpetuity, license, with a right to sublicense, in the Territory (Canada, the United States and Mexico) to the “Zeus Know-How” which consists of all information related to the manufacture and commercialization of saliva tests derived from patents owned by Zeus. The Company paid Zeus a one-time, non-refundable up-front cash fee of $35,000 (which is creditable against other payments due) and will pay Zeus a royalty on “Net Sales” (as defined in the License Agreement) of Seven and One-Half Percent (7.5%) during each calendar quarter.

Following the closing of the Acquisition, business will focus on the EZ Saliva product commercialization activity previously carried on by Point.

On October 2, 2024 the Company issued 1,270,000 shares of common stock to three investors and raised $30,000.00.

The description of the agreement discussed above does not purport to be complete and the reader should refer to the full text of the agreements attached hereto as exhibits.

F-14

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Point of Care Nano-Technology, Inc.

	By: /s/ Nicholas DeVito
	Nicholas DeVito
	Chief Executive Officer and Director
	(Principal Executive Officer) (Principal Financial and Accounting Officer)

	Date: October 29, 2024

In accordance with the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

SIGNATURE	TITLE	DATE

/s/ Nicholas DeVito	Chief Executive Officer, Chief	October 29, 2024
Nicholas DeVito	Financial Officer, President, Treasurer, Secretary and Director

/s/ Dr. Raouf Guirguis	Chief Science Officer, Director	October 29, 2024
Dr. Raouf Guirguis

/s/ Mr. Nathan Keele	Director	October 29, 2024
Mr. Nathan Keele

Filing Compare · Point of Care Nano-Technology, Inc.